Calcium orthophosphate-based biocomposites and hybrid biomaterials by unknown
REVIEW
Calcium orthophosphate-based biocomposites and hybrid
biomaterials
Sergey V. Dorozhkin
Received: 4 July 2008 / Accepted: 20 November 2008 / Published online: 15 January 2009
 Springer Science+Business Media, LLC 2009
Abstract In this review article, the state-of-the-art of
calcium orthophosphate-based biocomposites and hybrid
biomaterials suitable for biomedical applications is pre-
sented. This subject belongs to a rapidly expanding area of
science and research, because these types of biomaterials
offer many significant and exciting possibilities for hard
tissue regeneration. Through the successful combinations
of the desired properties of matrix materials with those of
fillers (in such systems, calcium orthophosphates might
play either role), innovative bone graft biomaterials can be
designed. The review starts with an introduction to locate
the reader. Further, general information on composites and
hybrid materials including a brief description of their major
constituents are presented. Various types of calcium
orthophosphate-based bone-analogue biocomposites and
hybrid biomaterials those are either already in use or being
investigated for various biomedical applications are then
extensively discussed. Many different formulations in
terms of the material constituents, fabrication technologies,
structural and bioactive properties, as well as both in vitro
and in vivo characteristics have been already proposed.
Among the others, the nano-structurally controlled bio-
composites, those with nanosized calcium orthophosphates,
biomimetically fabricated formulations with collagen,
chitin and/or gelatin, as well as various functionally graded
structures seem to be the most promising candidates for
clinical applications. The specific advantages of using
calcium orthophosphate-based biocomposites and hybrid
biomaterials in the selected applications are highlighted.
As the way from a laboratory to a hospital is a long one and
the prospective biomedical candidates have to meet many
different necessities, the review also examines the critical
issues and scientific challenges that require further research
and development.
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Introduction
The fracture of bones due to various traumas or natural
aging is a typical type of a tissue failure. An operative
treatment frequently requires implantation of a temporary
or a permanent prosthesis, which still is a challenge for
orthopedic surgeons, especially in the cases of large bone
defects. A fast aging of the population and serious draw-
backs of natural bone grafts make the situation even worse;
therefore, there is a high clinical demand for bone substi-
tutes. Unfortunately, a medical application of xenografts
(e.g., bovine bone) is generally associated with potential
viral infections. In addition, xenografts have a low oste-
ogenicity, an increased immunogenicity and, usually,
resorb more rapidly than autogenous bone. Similar limi-
tations are also valid for human allografts (i.e., tissue
transplantation between individuals of the same species but
of non-identical genetic composition), where the concerns
about potential risks of transmitting tumor cells, a variety
of bacterial and viral infections, as well as immunological
and blood group incompatibility are even stronger [1–3].
Moreover, harvesting and conservation of allografts
(exogenous bones) are additional limiting factors. Auto-
grafts (endogenous bones) are still the ‘‘golden standard’’
among any substitution materials because they are osteo-
genic, osteoinductive, osteoconductive, completely
biocompatible, non-toxic, and do not cause any immuno-
logical problems (non-allergic). They contain viable
osteogenic cells, bone matrix proteins, and support bone
growth. Usually, autografts are well accepted by the body
and rapidly integrated into the surrounding bone tissues.
Due to these reasons, they are used routinely for a long
period with good clinical results [3, 4]; however, it is fair to
say on complication cases, those frequently happened in
the past [5, 6]. Unfortunately, a limited number of donor
sites restrict the quantity of autografts harvested from the
iliac crest or other locations of the patient’s own body.
Also, their medical application is always associated with
additional traumas and scars resulting from the extraction
of a donor tissue during a superfluous surgical operation,
which requires further healing at the donation site and can
involve long-term postoperative pain [1, 6–9]. Thus, any
types of a biologically derived transplant appear to be
imperfect solutions, mainly due to a restricted quantity of
donor tissues, donor site morbidity, as well as potential
risks of an immunological incompatibility and disease
transfer [7, 9, 10]. In this light, man-made materials
(alloplastic or synthetic bone grafts) stand out as a rea-
sonable option because they are easily available, might
be processed and modified to suit the specific needs of
a given application [11, 12]. What’s more, there are
no concerns about potential infections, immunological
incompatibility, sterility, and donor site morbidity.
Therefore, investigations on artificial materials for bone
tissue repair appear to be one of the key subjects in the field
of biomaterials research for clinical applications [13].
Currently, there are several classes of synthetic bone
grafting biomaterials for in vivo applications [14–17]. The
examples include natural coral, coral-derived materials,
bovine porous demineralized bone, human demineralized
bone matrix, bioactive glasses, glass–ceramics, and cal-
cium orthophosphates [9]. All of these biomaterials are
biocompatible and osteoconductive, guiding bone tissue
from the edges toward the center of the defect, and aim to
provide a scaffold of interconnected pores with pore
dimensions ranging from 200 [18, 19] to 2 mm [20], to
facilitate tissue and vessel ingrowths. Among them, porous
bioceramics made of calcium orthophosphates appear to be
very prominent due to both the excellent biocompatibility
and bonding ability to living bone in the body. This is
directly related to the fact that the inorganic material of
mammalian calcified tissues, i.e., of bone and teeth, con-
sists of calcium orthophosphates [21–23]. Due to this
reason, other artificial materials are normally encapsulated
by fibrous tissue, when implanted in body defects, while
calcium orthophosphates are not [24]. Several types of
calcium orthophosphate-based bioceramics with different
chemical composition are already on the market [9, 25].
Unfortunately, as for any ceramic material, calcium
orthophosphate bioceramics by itself lack the mechanical
and elastic properties of the calcified tissues; namely,
scaffolds made of calcium orthophosphates only suffer
from a low elasticity, a high brittleness, a poor tensile
strength, a low mechanical reliability, and fracture tough-
ness, which leads to the concerns about their mechanical
performance after implantation [26–28]. Besides, in many
cases, it is difficult to form calcium orthophosphate
bioceramics into the desired shapes.
The superior strength and partial elasticity of biological
calcified tissues (e.g., bones) are due to the presence of
bioorganic polymers (mainly, collagen type I fibers1) rather
than to a natural ceramic (mainly, a poorly crystalline ion-
substituted calcium-deficient hydroxyapatite, often referred
to as ‘‘biological apatite’’) phase [30, 31]. The elastic
collagen fibers are aligned in bone along the main stress
directions. The biochemical composition of bone is given
in Table 1 [32]. A decalcified bone becomes very flexible
being easily twisted, whereas a bone without collagen is
very brittle; thus, the inorganic nanocrystals of biological
apatite provide with the hardness and stiffness, whereas the
bioorganic fibers are responsible for the elasticity and
1 One molecule of collagen type I is a triple helix with 338 repetitions
of amino acid residues and is about 300 nm in length [29].
Additionally, bone contains small quantities of other bioorganic
materials, such as proteins, polysaccharides, and lipids, as well as
bone contains cells and blood vessels.
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toughness [22, 33]. In bones, both types of materials inte-
grate each other into a nanometric scale in such a way that
the crystallite size, fibers orientation, short-range order
between the components, etc. determine its nanostructure
and therefore the function and mechanical properties of the
entire composite [29, 34–38]. From the mechanical point of
view, bone is a tough material at low strain rates but
fractures more like a brittle material at high strain rates;
generally, it is rather weak in tension and shear, particu-
larly along the longitudinal plane. Besides, bone is an
anisotropic material because its properties are directionally
dependent [21, 22, 28].
It remains a great challenge to design the ideal bone
graft that emulates nature’s own structures or functions.
Certainly, the successful design requires an appreciation of
the structure of bone. According to expectations, the ideal
bone graft should be benign, available in a variety of forms
and sizes; all with sufficient mechanical properties for use
in load-bearing sites form a chemical bond at the bone/
implant interface, as well as be osteogenic, osteoinductive,
osteoconductive, biocompatible, completely biodegradable
at the expense of bone growth and moldable to fill and
restore bone defects [26, 36, 39]. Further, it should
resemble the chemical composition of bones (thus, the
presence of calcium orthophosphates is mandatory), exhibit
contiguous porosity to encourage invasion by the live host
tissue, as well as possess both viscoelastic and semi-brittle
behavior, as bones do [40–43]. Moreover, the degradation
kinetics of the ideal implant should be adjusted to the
healing rate of the human tissue with absence of any
chemical or biological irritation and/or toxicity caused by
substances, which are released due to corrosion or degra-
dation. Ideally, the combined mechanical strength of the
implant and the ingrowing bone should remain constant
throughout the regenerative process. Furthermore, the
substitution implant material should not disturb signifi-
cantly the stress environment of the surrounding living
tissue [44]. Finally, there is an opinion, that in the case of a
serious trauma, bone should fracture rather than the implant
[26]. A good sterilizability, storability, and processability,
as well as a relatively low cost are also of a great impor-
tance to permit a clinical application. Unfortunately, no
artificial biomaterial is yet available, which embodies all
these requirements and unlikely it will appear in the nearest
future. Until now, most of the available biomaterials appear
to be either predominantly osteogenic or osteoinductive or
else purely osteoconductive [2].
Careful consideration of the bone type and mechanical
properties are needed to design bone substitutes. Indeed, in
high load-bearing bones such as the femur, the stiffness of
the implant needs to be adequate, not too stiff to result in
strain shielding, but rigid enough to present stability.
However, in relatively low load-bearing applications such
as cranial bone repairs, it is more important to have sta-
bility and the correct three-dimensional shapes for esthetic
reasons. One of the most promising alternatives is to apply
materials with similar composition and nanostructure to
that of bone tissue [36]. Mimicking the structure of calci-
fied tissues and addressing the limitations of the individual
materials, development of organic–inorganic hybrid bio-
materials provides excellent possibilities for improving the
conventional bone implants. In this sense, suitable bio-
composites of tailored physical, biological, and mechanical
properties with the predictable degradation behavior can
be prepared by combining biologically relevant calcium
orthophosphates with bioresorbable polymers [45, 46]. As
a rule, the general behavior of these bioorganic/calcium
orthophosphate composites is dependent on nature, struc-
ture, and relative contents of the constitutive components,
although other parameters such as the preparation condi-
tions also determine the properties of the final materials.
Currently, biocomposites with calcium orthophosphates
incorporated as either a filler or a coating (or both) either
into or onto a biodegradable polymer matrix, in the form of
particles or fibers, are increasingly considered for using as
bone tissue engineering scaffolds due to their improved
physical, biological, and mechanical properties [47–53].
In addition, such biocomposites could fulfill general
Table 1 The biochemical
composition of bone [32]
The composition is varied from
species to species and from
bone to bone
Inorganic phases wt% Bioorganic phases wt%
Calcium orthophosphates
(biological apatite)
*60 Collagen type I *20
Water *9 Non-collagenous proteins: osteocalcin, osteonectin,
osteopontin, thrombospondin, morphogenetic
proteins, sialoprotein, serum proteins
*3
Carbonates *4 Other traces: polysaccharides, lipids, cytokines Balance
Citrates *0.9 Primary bone cells: osteoblasts, osteocytes, osteoclasts Balance
Sodium *0.7
Magnesium *0.5
Other traces: Cl-, F-, K?
Sr2?, Pb2?, Zn2?, Cu2?,
Fe2?
Balance
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requirements to the next generation of biomaterials, those
should combine the bioactive and bioresorbable properties
to activate in vivo mechanisms of tissue regeneration,
stimulating the body to heal itself and leading to the
replacement of the implants by the regenerating tissue [46,
54, 55]. Thus, through the successful combinations of
ductile polymer matrixes with hard and bioactive particu-
late bioceramic fillers, optimal materials can be designed
and, ideally, this approach could lead to a superior con-
struction to be used as either implants or posterior dental
restorative material [56].
A lint-reinforced plaster was the first composite used in
clinical orthopedics as an external immobilizer (bandage)
in the treatment of bone fracture by Mathijsen in 1852 [57],
followed by Dreesman in 1892 [58]. A great progress in the
clinical application of various types of composite materials
has been achieved since then. Based on the previous
experience and newly gained knowledge, various com-
posite materials with tailored mechanical and biological
performance can be manufactured and used to meet various
clinical requirements [59]. However, this review presents
only a brief history and advances in the field of calcium
orthophosphate-based biocomposites and hybrid biomate-
rials suitable for biomedical application. The majority of
the reviewed literature is restricted to the recent publica-
tions; a limited number of papers published in the 20th
century have been cited. Various aspects of the material
constituents, fabrication technologies, structural and bio-
active properties, and phase interaction have been
considered and discussed in details. Finally, several critical
issues and scientific challenges that are needed for further
advancement are outlined.
General information on composites and biocomposites
According to Wikipedia, the free encyclopedia, ‘‘composite
materials (or composites for short) are engineered materials
made from two or more constituent materials with signif-
icantly different physical or chemical properties and which
remain separate and distinct on a macroscopic level within
the finished structure’’ [60]. Thus, composites are always
heterogeneous. Following the point of view of some pre-
decessors, we also consider that ‘‘for the purpose of this
review, composites are defined as those having a distinct
phase distributed through their bulk, as opposed to modular
or coated components’’ [61, p. 1329]. For this reason, with
a few important exceptions, the structures obtained by
soaking of various materials in supersaturated solutions
containing ions of calcium and orthophosphate (e.g., Refs.
[62–67]), those obtained by coating of various materials by
calcium orthophosphates (e.g., Refs. [68–73]), as well as
calcium orthophosphates coated by other compounds [74]
have not been considered; however, composite coatings
have been considered. Occasionally, porous calcium
orthophosphate scaffolds filled by cells inside the pores
[75, 76], as well as calcium orthophosphates impregnated
by biologically active substances [77] are also defined as
composites; nevertheless, such structures have not been
considered in this review either.
In any composite, there are two major categories of
constituent materials: a matrix (or a continuous phase) and
(a) dispersed phase(s). In order to create a composite, at
least one portion of each type is required. General infor-
mation on the major fabrication and processing techniques
might be found elsewhere [61]. The continuous phase is
responsible for filling the volume, as well as it surrounds,
and supports the dispersed material(s) by maintaining their
relative positions. The dispersed phase(s) is(are) usually
responsible for enhancing one or more properties of the
matrix. Most of the composites target an enhancement
of mechanical properties of the matrix, such as stiffness
and strength; however, other properties, such as erosion
stability, transport properties (electrical or thermal), radi-
opacity, density, or biocompatibility, might also be of a
great interest. This synergism produces the properties,
which are unavailable from the individual constituent
materials [78]. What’s more, by controlling the volume
fractions and local and global arrangement of the dispersed
phase, the properties and design of composites can be
varied and tailored to suit the necessary conditions. For
example, in the case of ceramics, the dispersed phase
serves to impede crack growth. In this case, it acts as
reinforcement. A number of methods, including deflecting
crack tips, forming bridges across crack faces, absorbing
energy during pullout and causing a redistribution of
stresses in regions adjacent to crack tips, can be used to
accomplish this [79]. Other factors to be considered in
composites are the volume fraction of (a) dispersed pha-
se(s), its(their) orientation and homogeneity of the overall
composite. For example, higher volume fractions of rein-
forcement phases tend to improve the mechanical
properties of the composites, while continuous and aligned
fibers best prevent crack propagation with the added
property of anisotropic behavior. Furthermore, the uniform
distribution of the dispersed phase is also desirable, as it
imparts consistent properties to the composite [60, 78].
In general, composites might be simple, complex, gra-
ded, and hierarchical. The term ‘‘a simple composite’’ is
referred to the composites those result from the homoge-
neous dispersion of one dispersed phase throughout a
matrix. The term ‘‘a complex composite’’ is referred to the
composites those result from the homogeneous dispersion
of several dispersed phases throughout one matrix.
The term ‘‘a graded composite’’ is referred to the com-
posites those result from the intentionally structurally
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inhomogeneous dispersion of one or several dispersed
phases throughout one matrix. The term ‘‘a hierarchical
composite’’ is referred to the cases, when fine entities of
either a simple or a complex composite is somehow
aggregated to form coarser ones (e.g., granules or particles)
which afterwards are dispersed inside another matrix to
produce the second hierarchical scale of the composite
structure. Another classification type of the available
composites is based on either the matrix materials (metals,
ceramics and polymers) or the reinforcement dimensions/
shapes (particulates, whiskers/short fibers, and continuous
fibers) [59].
In most cases, three interdependent factors must be
considered in designing of any composite: (i) selection of
the suitable matrix and dispersed materials, (ii) choice of
appropriate fabrication and processing methods, (iii)
internal and external designs of the device itself [61].
Besides, any composite must be formed to shape. To do
this, the matrix material can be added before or after the
dispersed material has been placed into a mold cavity or
onto the mold surface. The matrix material experiences a
melding event, depending upon the nature of the matrix
material, that can occur in various ways such as chemical
polymerization, setting, curing, or solidification from a
melted state. Due to a general inhomogeneity, the physical
properties of many composite materials are not isotropic,
but rather orthotropic (i.e., there are different properties or
strengths in different orthogonal directions) [60, 78].
Biocomposites are defined as the composites able to
interact well with the human body in vivo and, ideally,
contain one or more component that stimulates the healing
process and uptake of the implant. Thus, for biocomposites
the biological compatibility appears to be more important
than any other type of compatibility [59]. The most com-
mon properties from the bioorganic and inorganic domains
to be combined in biocomposites have been summarized in
Table 2 [36]. In 1990, Williams summarized the major
types of biocomposites that were used in orthopedic
applications that time [80]. In 2003, Wang published an
excellent update [81]. For general advantages of the
modern calcium orthophosphate-based biocomposites over
calcium orthophosphate bioceramics and bioresorbable
polymers individually, the interested readers are advised to
get through ‘‘Composite materials strategy’’ chapter of Ref.
[46].
The major constituent materials of biocomposites
for biomedical applications
Calcium orthophosphates
The main driving force behind the use of calcium ortho-
phosphates as bone substitute materials is their chemical
similarity to the mineral component of mammalian bones
and teeth [21–23]. As a result, in addition to being non-
toxic, they are biocompatible, not recognized as foreign
materials in the body and, most importantly, both exhibit
bioactive behavior and integrate into living tissue by the
same processes active in remodeling healthy bone. This
leads to an intimate physicochemical bond between the
implants and bone, termed osteointegration [81]. More to
the point, calcium orthophosphates are also known to
support osteoblast adhesion and proliferation [82, 83].
Even so, the major limitations to use calcium orthophos-
phates as load-bearing biomaterials are their mechanical
properties; namely, they are brittle with poor fatigue
resistance [26–28]. The poor mechanical behavior is even
more evident for highly porous ceramics and scaffolds
because porosity[100 lm is considered as the requirement
for proper vascularization and bone cell colonization [84–
86], i.e., why, in biomedical applications calcium ortho-
phosphates are used primarily as fillers and coatings [23].
The complete list of known calcium orthophosphates,
including their standard abbreviations and the major
properties, is given in Table 3, while the detailed infor-
mation on calcium orthophosphates, their synthesis,
structure, chemistry, other properties, and biomedical
application have been comprehensively reviewed recently
[23], where the interested readers are referred to. Even
thorough more information might be found in various
books and monographs [87–93].
Polymers
Polymers are a class of materials consisting of large mol-
ecules, often containing many thousands of small units, or
monomers, joined together chemically to form one giant
chain, thus creating very ductile materials. In this respect,
polymers are comparable with major functional compo-
nents of the biological environment: lipids, proteins,
and polysaccharides. They differ from each other in
chemical composition, molecular weight, polydispersity,
Table 2 General respective properties from the bioorganic and
inorganic domains, to be combined in various composites and hybrid
materials [36]
Inorganic Bioorganic
Hardness, brittleness Elasticity, plasticity
High density Low density
Thermal stability Permeability
Hydrophilicity Hydrophobicity
High refractive index Selective complexation
Mixed valence slate (red-ox) Chemical reactivity
Strength Bioactivity
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crystallinity, hydrophobicity, solubility, and thermal tran-
sitions. Besides, their properties can be fine-tuned over a
wide range by varying the type of polymer, chain length, as
well as by copolymerization or blending of two or more
polymers [94, 95]. Opposite to ceramics, polymers exhibit
substantial viscoelastic properties and can easily be fabri-
cated into complex structures, such as sponge-like sheets,
gels, or complex structures with intricate porous networks
and channels [96]. X-ray transparent and non-magnetic
polymeric materials are fully compatible with the modern
diagnostic methods such as computed tomography and
magnetic resonance imaging. Unfortunately, most of them
are unable to meet the strict demands of the in vivo
physiological environment. Namely, the main requirements
to polymers suitable for biomedical applications are that
they must be biocompatible, not eliciting an excessive or
chronic inflammatory response upon implantation and, for
those that degrade, that they breakdown into non-toxic
products only. Unfortunately, polymers, for the most part,
lack rigidity, ductility, and ultimate mechanical properties
required in load-bearing applications. Moreover, the ster-
ilization processes (autoclave, ethylene oxide, and 60Co
irradiation) may affect the polymer properties [97].
There is a variety of biocompatible polymers suitable for
biomedical applications. For example, polyacrylates,
poly(acrylonitrile-co-vinylchloride) and polylysine have
been investigated for cell encapsulation and immunoiso-
lation [98, 99]. Polyorthoesters and poly(e-caprolactone)
(PCL) have been investigated as drug-delivery devices, the
latter for long-term sustained release because of their slow
degradation rates [100]. PCL is a hydrolytic polyester
having appropriate resorption period and releases non-toxic
byproducts upon degradation [101]. Other polyesters and
polytetrafluoroethylene (PTFE) are used for vascular tissue
replacement. Polyurethanes are in use as coatings for
pacemaker lead insulation and have been investigated for
reconstruction of the meniscus [102, 103]. Polymers con-
sidered for orthopedic purposes include polyanhydrides,
which have also been investigated as delivery devices (due
to their rapid and well-defined surface erosion), for bone
Table 3 Existing calcium orthophosphates and their major properties
Ca/P ionic
ratio
Compound Chemical formula Solubility
at 25 C,
-log(Ks)




solutions at 25 C
0.5 Monocalcium phosphate
monohydrate (MCPM)
Ca(H2PO4)2  H2O 1.14 Data not found 0.0–2.0
0.5 Monocalcium phosphate
anhydrous (MCPA)
Ca(H2PO4)2 1.14 Data not found
a
1.0 Dicalcium phosphate dihydrate
(DCPD), mineral brushite
CaHPO4  2H2O 6.59 6.63 2.0–6.0




1.33 Octacalcium phosphate (OCP) Ca8(HPO4)2(PO4)4  5H2O 96.6 95.9 5.5–7.0
1.5 a-Tricalcium phosphate (a-TCP) a-Ca3(PO4)2 25.5 25.5
b
1.5 b-Tricalcium phosphate (b-TCP) b-Ca3(PO4)2 28.9 29.5
b
1.2–2.2 Amorphous calcium phosphate
(ACP)
CaxHy(PO4)z  nH2O,






f (0 \ x \ 1)
*85.1 *85.1 6.5–9.5
1.67 Hydroxyapatite (HA) Ca10(PO4)6(OH)2 116.8 117.2 9.5–12
1.67 Fluorapatite (FA) Ca10(PO4)6F2 120.0 119.2 7–12




The solubility is given as the logarithm of the ion product of the given formulae (excluding hydrate water) with concentrations in mol/L [23]
a Stable at temperatures above 100 C
b These compounds cannot be precipitated from aqueous solutions
c Cannot be measured precisely. However, the following values were found: 25.7 ± 0.1 (pH = 7.40), 29.9 ± 0.1 (pH = 6.00), 32.7 ± 0.1
(pH = 5.28)
d Always metastable
e Occasionally, CDHA is named as precipitated HA
f In the case x = 1 (the boundary condition with Ca/P = 1.5), the chemical formula of CDHA looks as follows: Ca9(HPO4)(PO4)5(OH)
2348 J Mater Sci (2009) 44:2343–2387
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augmentation or replacement since they can be photopo-
lymerized in situ [100, 104, 105]. To overcome their poor
mechanical properties, they have been copolymerized with
imides or formulated to be crosslinkable in situ [105].
Other polymers, such as polyphosphazenes, can have their
properties (e.g., degradation rate) easily modified by
varying the nature of their side groups and have been
shown to support osteoblast adhesion, which makes them
candidate materials for skeletal tissue regeneration [105].
PPF has emerged as a good bone replacement material,
exhibiting good mechanical properties (comparable to
trabecular bone), possessing the capability to crosslink in
vivo through the C=C bond and being hydrolytically
degradable. It has also been examined as a material for
drug-delivery devices [100, 104–107]. Polycarbonates have
been suggested as suitable materials to make scaffolds for
bone replacement and have been modified with tyrosine-
derived amino acids to render them biodegradable [100].
Polydioxanone has been also tested for biomedical appli-
cations [108]. Polymethylmethacrylate (PMMA) is widely
used in orthopedics, as a bone cement for implant fixation,
as well as to repair certain fractures and bone defects, for
example, osteoporotic vertebral bodies [109]. However,
PMMA sets by a polymerization of toxic monomers, which
also evolves significant amounts of heat that damages tis-
sues. Moreover, it is neither degradable nor bioactive, it
does not bond chemically to bones and might generate
particulate debris leading to an inflammatory foreign body
response [104, 110]. A number of other non-degradable
polymers applied in orthopedic surgery include PE in its
different modifications such as low density PE, high-den-
sity polyethylene (HDPE), and Ultrahigh molecular weight
polyethylene (used as the articular surface of total hip
replacement implants [111, 112]), polyethylene tereptha-
late, polypropylene, and PTFE, which are applied to repair
knee ligaments [113]. PolyactiveTM, a block copolymer of
polyethylene glycol (PEG) and polybutyleneterephthalate
(PBT), was also considered for biomedical application
[114–118]. Cellulose [119] and its esters [120] are also
popular. Finally yet importantly, polyethylene oxide,
polyhydroxybutyrate (PHB), and blends thereof have also
been tested for biomedical applications [46].
Nonetheless, the most popular synthetic polymers used
in medicine are the linear aliphatic poly(a-hydroxyesters)
such as PLA, polyglycolic acid (PGA) and their copoly-
mers—poly(lactic-co-glycolic) acid (PLGA) (Table 4).
These materials have been extensively studied; they appear
to be the only synthetic and biodegradable polymers with
an extensive FDA approval history [46, 105, 121–125].
They are biocompatible, mostly non-inflammatory, as well
as degrade in vivo through hydrolysis and possible enzy-
matic action into products that are removed from the body
by regular metabolic pathways [45, 100, 105, 125–130].
Besides, they might be used for drug-delivery purposes
[131]. Poly(a-hydroxyesters) have been investigated as
scaffolds for replacement and regeneration of a variety of
tissues, cell carriers, controlled delivery devices for drugs
or proteins (e.g., growth factors), membranes or films,
screws, pins, and plates for orthopedic applications [100,
103, 105, 122, 125, 132–134]. Additionally, the degrada-
tion rate of PLGA can be adjusted by varying the amounts
of the two component monomers (Table 4), which in
orthopedic applications can be exploited to create materials
that degrade in concert with bone ingrowth [129, 135].
Furthermore, PLGA is known to support osteoblast
migration and proliferation [55, 105, 126, 136], which is a
necessity for bone tissue regeneration. Unfortunately, such
polymers on their own, though they reduce the effect of
stress-shielding, are too weak to be used in load-bearing
situations and are only recommended in certain clinical
indications, such as ankle and elbow fractures [125, 130].
In addition, they exhibit bulk degradation, leading to both a
loss in mechanical properties and lowering of the local
solution pH that accelerates further degradation in an
Table 4 Major properties of several FDA approved biodegradable polymers [121]




Polyglycolic acid (PGA) tg = 35–40, tm = 225–230 7.06 6–12 (strength loss
within 3 weeks)
L-polylactic acid (LPLA) tg = 60–65, tm = 173–178 2.7 [24
D,L-polylactic acid (DLPLA) tg = 55–60 amorphous 1.9 12–16
85/15 D,L-polylactic-co-glycolic acid (85/15 DLPLGA) tg = 50–55 amorphous 2.0 5–6
75/25 D,L-polylactic-co-glycolic acid (75/25 DLPLGA) tg = 50–55 amorphous 2.0 4–5
65/35 D,L-polylactic-co-glycolic acid (65/35 DLPLGA) tg = 45–50 amorphous 2.0 3–4
50/50 D,L-polylactic-co-glycolic acid (50/50 DLPLGA) tg = 45–50 amorphous 2.0 1–2
PCL tg = (–60)–(–65), tm = 58–63 0.4 [24
a tg glass transition temperature, tm melting point
J Mater Sci (2009) 44:2343–2387 2349
123
autocatalytic manner. As the body is unable to cope with
the vast amounts of implant degradation products, this
might lead to an inflammatory foreign body response [105,
125, 132]. Finally, poly(a-hydroxyesters) do not possess
the bioactive and osteoconductive properties of calcium
orthophosphates [122, 137].
Several classifications of the biomedically relevant
polymers are possible. For example, some authors distin-
guish between synthetic polymers like PLA and PGA or
their copolymers with PCL, and polymers of biological
origin like polysaccharides (starch, alginate, chitin/chito-
san2 [138–140], gelatin, cellulose, hyaluronic acid
derivatives), proteins (soy, collagen, fibrin [9], silk), and a
variety of biofibers, such as lignocellulosic natural fibers
[8, 141, 142]. Other authors differentiate between resorb-
able or biodegradable (e.g., poly(a-hydroxyesters), polysac-
charides and proteins) and non-resorbable (e.g., PE,
PMMA, and cellulose) polymers [56, 142]. As synthetic
polymers can be produced under the controlled conditions,
they in general exhibit predictable and reproducible
mechanical and physical properties such as tensile strength,
elastic modulus, and degradation rate. Control of impurities
is a further advantage of synthetic polymers. The list of
synthetic biodegradable polymers used for biomedical
application as scaffold materials is available as Table 1 in
Ref. [142], while further details on polymers suitable for
biomedical applications are available in the literatures
[97, 134, 143–151] where the interested readers are referred.
Good reviews on the synthesis of different biodegradable
polymers [152], as well as on the experimental trends in
polymer nanocomposites [153] are available elsewhere.
Inorganic materials and compounds (metals, ceramics,
glass, oxides, carbon, etc.)
Titanium (Ti) is one of the best biocompatible metals and
used most widely as implant [13, 154]. Besides, there are
other metallic implants made of pure Zr, Hf, V, Nb, Ta, Re
[154], Ni, Fe, Cu [155–157], Ag, stainless steels, and
various alloys [157] suitable for biomedical application.
Recent studies revealed even a greater biomedical potential
of porous metals [158–160]. The metallic implants provide
the necessary strength and toughness that are required in
load-bearing parts of the body and, due to these advanta-
ges, metals will continue to play an important role as
orthopedic biomaterials in the future, even though there are
concerns with regard to the release of certain ions from and
corrosion products of metallic implants. Of course, neither
metals nor alloys are biomimetic3 in terms of chemical
composition because there are no elemental metals in the
human body. In addition, even biocompatible metals are
bioinert: while not rejected by the human body, any
metallic implants cannot actively interact with the sur-
rounding tissues. Nevertheless, in some cases (especially
when they are coated by calcium orthophosphates; how-
ever, that is another story) the metallic implants can show a
reasonable biocompatibility [162]. Only permanent
implants are made of metals and alloys, in which degra-
dation or corrosion is not desirable. However, during recent
years a number of magnesium alloys have been proposed,
which are aimed to degrade in the body in order to make
room for the ingrowing bone [160, 163].
Special types of glasses and glass ceramics are also
suitable materials for biomedical applications [164–166]
and a special Na2O–CaO–SiO2–P2O5 glass named Bio-
glass [11, 24, 27, 28, 167, 168] is the most popular
among them. They are produced via standard glass pro-
duction techniques and require pure raw materials.
Bioglass is a biocompatible and osteoconductive bio-
material. It bonds to bone without an intervening fibrous
connective tissue interface and, due to these properties, it
has been widely used for filling bone defects [169]. The
primary shortcoming of Bioglass is mechanical weak-
ness and low fracture toughness due to an amorphous
two-dimensional glass network. The bending strength of
most Bioglass compositions is in the range of 40 to
60 MPa, which is not suitable for major load-bearing
applications. Making porosity in Bioglass-based scaf-
folds is beneficial for even better resorption and bio-
activity [170].
By heat treatment, a suitable glass can be converted into
glass–crystal composites containing crystalline phase(s) of
controlled sizes and contents. The resultant glass ceramics
can have superior mechanical properties to the parent glass
as well as to sintered crystalline ceramics. The bioactive
apatite–wollastonite (A-W) glass ceramics is made from
the parent glass in the pseudoternary system 3CaO  P2O5–
CaO  SiO2–MgO  CaO  2SiO2, which is produced by a
conventional melt-quenching method. The bioactivity of
A-W glass ceramics is much higher than that of sintered
HA. It possesses excellent mechanical properties and has
therefore been used clinically for iliac and vertebrae
prostheses and as intervertebral spacers [13, 171, 172].
Metal oxide ceramics, such as alumina (Al2O3, high
purity, polycrystalline, fine grained), zirconia (ZrO2), and
some other oxides (e.g., TiO2), have been widely studied
due to their bioinertness, excellent tribological properties,
2 Chitosan is a biodegradable and semicrystalline polysaccharide
obtained from N-deacetylation of chitin, which is harvested from the
exoskeleton of marine crustaceans.
3 The term biomimetic can be defined as a processing technique that
either mimics or inspires the biological mechanism, in part or whole
[161].
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high wear resistance, fracture toughness and strength, as
well as a relatively low friction [13, 173]. Unfortunately,
due to transformation from the tetragonal to the monoclinic
phase, a volume change occurs when pure zirconia is
cooled down, which causes cracking of the zirconia
ceramics. Therefore, additives such as calcia (CaO), mag-
nesia (MgO), and yttria (Y2O3) must be mixed with
zirconia to stabilize the material in either the tetragonal or
the cubic phase. Such material is called PSZ [174–176].
However, the brittle nature of any ceramics has limited
their scope of clinical applications and hence more research
needs to be conducted to improve their properties.
Calcium orthophosphate-based biocomposites
and hybrid biomaterials
Generally, the use of calcium orthophosphate-based
biocomposites and hybrid biomaterials for clinical appli-
cations has included several (partly overlapping) broad
areas:
• biocomposites with polymers,
• cement-based biocomposites and concretes,
• nano-calcium orthophosphate-based biocomposites and
nanocomposites,
• biocomposites with collagen,
• biocomposites with other bioorganic compounds and
biological macromolecules,
• injectable bone substitutes (IBS),
• biocomposites with glasses, inorganic compounds, and
metals,
• functionally graded biocomposites,
• biosensors.
The details of each subject are given below.
Biocomposites with polymers
Typically, the polymeric components of biocomposites and
hybrid biomaterials comprise polymers that both have
shown a good biocompatibility and are routinely used in
surgical applications. In general, since polymers have a low
modulus (2–7 GPa, as the maximum) as compared with
that of bone (3–30 GPa), calcium orthophosphate bioce-
ramics need to be loaded at a high-weight-percent ratio.
Besides, general knowledge on composite mechanics sug-
gests that any high-aspect-ratio particles, such as whiskers
or fibers, significantly improve the modulus at a lower
loading [147]. Thus, some attempts have been already
performed to prepare biocomposites containing whisker-
like [177–180] or needle-like [181–183] calcium ortho-
phosphates, as well as calcium orthophosphate fibers [45,
184].
The history of implantable polymer–calcium ortho-
phosphate biocomposites and hybrid biomaterials started in
19814 from the pioneering study by Prof. William Bonfield
and colleagues performed on HA/PE composites [186,
187]. That initial study introduced a bone-analogue con-
cept, when proposed biocomposites comprised a polymer
ductile matrix of PE and a ceramic stiff phase of HA, and
was substantially extended and developed in further
investigations by that research group [94, 188–205]. More
recent studies included investigations on the influence of
surface topography of HA/PE composites on cell prolifer-
ation and attachment [206–212]. The material is composed
of a particular combination of HA particles at a volume
loading of *40% uniformly dispensed in a HDPE matrix.
The idea was to mimic bone by using a polymeric matrix
that can develop a considerable anisotropic character
through adequate orientation techniques reinforced with a
bone-like ceramics that assures both a mechanical rein-
forcement and a bioactive character of the composite.
Following FDA approval in 1994, in 1995 this material has
become commercially available under the trade name
HAPEXTM (Smith and Nephew, Richards, USA), and until
now remains the only clinically successful bioactive com-
posite that appeared to be a major step in the implant field
[28, 213]. The major production stages of HAPEXTM
include blending, compounding, and centrifugal milling. A
bulk material or device is then created from this powder by
compression and injection molding [59]. Besides, HA/
HDPE biocomposites might be prepared by a hot rolling
technique that facilitated uniform dispersion and blending
of the reinforcements in the matrix [214].
A mechanical interlock between the two phases of
HAPEXTM is formed by shrinkage of HDPE onto the HA
particles during cooling [94, 215]. Both HA particle size
and their distribution in the HDPE matrix were recognized
as important parameters affecting the mechanical behavior
of HAPEXTM [197]. Namely, smaller HA particles were
found to lead to stiffer composites due to general increas-
ing of interfaces between the polymer and the ceramics;
furthermore, rigidity of HAPEXTM was found to be pro-
portional to HA volume fraction [189]. In this formulation,
HA could be replaced by other calcium orthophosphates
[216].
Initial clinical applications of HAPEXTM came in orbital
reconstruction [217] but since 1995, the main uses of this
composite have been in the shafts of middle ear implants
for the treatment of conductive hearing loss [218, 219]. In
both applications, HAPEXTM offers the advantage of in
situ shaping, so a surgeon can make final alterations to
optimize the fit of the prosthesis to the bone of a patient
4 However, a more general topic ‘‘ceramic–plastic material as a bone
substitute’’ is, at least, 18 years older [185].
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and subsequent activity requires only limited mechanical
loading with virtually no risk of failure from insufficient
tensile strength [94, 167]. As compared with cortical bones,
HA/PE composites have a superior fracture toughness for
HA concentrations below 40% and similar fracture
toughness in the 45–50% range. Their Young’s modulus is
in the range of 1 to 8 GPa, which is quite close to that of
bone. The examination of the fracture surfaces revealed
that only mechanical bond occurs between HA and PE.
Unfortunately, the HA/PE composites are not biodegrad-
able, the available surface area of HA is low and the
presence of bioinert PE decreases the ability to bond to
bones. Furthermore, HAPEXTM has been designed with a
maximized density to increase its strength but the resulting
lack of porosity limits the ingrowth of osteoblasts when the
implant is placed into the body [26, 168]. Further details on
HAPEXTM are available elsewhere [94]. Except of HAP-
EXTM, other types of HA/PE biocomposites are also known
[220–224].
Both linear and branched PE was used as a matrix and
the biocomposites with the former were found to give a
higher modulus [221]. The reinforcing mechanisms in
calcium orthophosphate/polymer biocomposites have yet to
be convincingly disclosed. Generally, if a poor filler choice
is made, the polymeric matrix might be affected by the
filler through reduction of molecular weight during com-
posite processing, formation of an immobilized shell of
polymer around the particles (transcrystallization, surface-
induced crystallization, or epitaxial growth) and changes in
conformation of the polymer due to particle surfaces and
inter-particle spacing [94]. On the other hand, the rein-
forcing effect of calcium orthophosphate particles might
depend on the molding technique employed: a higher ori-
entation of the polymeric matrix was found to result in a
higher mechanical performance of the composite [225,
226].
Many other blends of calcium orthophosphates with
various polymers are possible, including rather unusual
formulations with dendrimers [227]. The list of the
appropriate calcium orthophosphates is shown in Table 3
(except of MCPM and MCPA—both are too acidic and,
therefore, are not biocompatible [23]), while many biom-
edically suitable polymers have been listed above. The
combination of calcium orthophosphates and polymers into
biocomposites has a twofold purpose. The desirable
mechanical properties of polymers compensate for a poor
mechanical behavior of calcium orthophosphate bioce-
ramics, while in turn the desirable bioactive properties of
calcium orthophosphates improve those of polymers,
expanding the possible uses of each material within the
body [127–129, 228–231]. Namely, polymers have been
added to calcium orthophosphates in order to improve
their mechanical strength [127, 228] and calcium
orthophosphate fillers have been blended with polymers to
improve their compressive strength and modulus, in addi-
tion to increase their osteoconductive properties [48, 129,
137, 232–236]. Furthermore, biocompatibility of such
biocomposites is enhanced because calcium orthophos-
phate fillers induce an increased initial flash spread of
serum proteins compared with the more hydrophobic
polymer surfaces [237]. What’s more, experimental results
of these biocomposites indicate favorable cell–material
interactions with increased cell activities as compared with
each polymer alone [230]. As a rule, with increasing of
calcium orthophosphate content, both Young’s modulus
and bioactivity of the biocomposites increase, while the
ductility decreases [26, 232]. Furthermore, such formula-
tions can provide a sustained release of calcium and
orthophosphate ions into the milieus, which is important
for mineralized tissue regeneration [229]. Indeed, a com-
bination of two different materials draws on the advantages
of each one to create a superior biocomposite with respect
to the materials on their own.
It is logical to assume that the proper biocomposite of a
calcium orthophosphate (for instance, CDHA) with a bio-
organic polymer (for instance, collagen) would yield the
physical, chemical, and mechanical properties similar to
those of human bones. Different ways have been already
realized to bring these two components together into
composites, like mechanical blending, ball milling, dis-
persion of ceramic fillers into a polymer–solvent solution, a
melt extrusion of a ceramic/polymer powder mixture,
coprecipitation, and electrochemical codeposition [32, 59,
238–240]. Besides, there is an in situ formation, which
involves either synthesizing the reinforcement inside a
preformed matrix material or synthesizing the matrix
material around the reinforcement [59, 241]. For example,
several papers have reported this method to produce vari-
ous composites of apatites with carbon nanotubes [242–
247]. Another example comprises using amino acid-capped
gold nanoparticles as scaffolds to grow CDHA [248]. In
certain cases, a mechano-chemical route [249], emulsions
[250–253], freeze-drying [254] and freeze-thawing tech-
niques [255], flame-sprayed technique [256], or gel-
templated mineralization [257] might be applied to produce
calcium othophosphates-based biocomposites. Various
fabrication procedures are available elsewhere [32, 59,
238], where the interested readers are referred.
The interfacial bonding between a calcium orthophos-
phate and a polymer is an important issue of any
biocomposite. If adhesion between the phases is poor, the
mechanical properties of a biocomposite suffer. In order to
solve the problem, various approaches have been already
introduced. For example, a diisocyanate coupling agent
was used to bind PEG/PBT (Polyactive
TM
) block copoly-
mers to HA filler particles. Using surface-modified HA
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particles as a filler in a PEG/PBT matrix significantly
improved the elastic modulus and strength of the polymer
as compared with the polymers filled with ungrafted HA
[234, 258]. Another group used processing conditions to
achieve a better adhesion of the filler to the matrix.
Ignjatovic et al. [127, 128, 259] prepared poly(L-lactic
acid) (PLLA)/HA composites by pressing blends of vary-
ing PLLA and HA content at different temperatures and
pressures. They found that maximum compressive strength
was achieved at *15 wt% of PLLA. Using blends with
20 wt% of PLLA, the authors also established that
increasing the pressing temperature and pressure improved
the mechanical properties. The former was explained by
decrease in viscosity of the PLLA associated with a tem-
perature increase, hence leading to improved wettability of
HA particles. The latter was explained by increased com-
paction and penetration of pores at higher pressure, in
conjunction with a greater fluidity of the polymer at higher
temperatures. The combination of high pressures and
temperatures was found to decrease porosity and guarantee
a close apposition of a polymer to the particles, thereby
improving the compressive strength [228] and fracture
energy [260] of the biocomposites. The PLLA/HA bio-
composites scaffolds were found to improve cell survival
over plain PLLA scaffolds [261].
It is also possible to introduce porosity into calcium
orthophosphate-based biocomposites, which is advanta-
geous for most applications as bone substitution material.
The porosity facilitates the migration of osteoblasts from
surrounding bones to the implant site [129, 262, 263].
Various material processing strategies to prepare compos-
ite scaffolds with interconnected porosity comprise
thermally induced phase separation, solvent casting, and
particle leaching, solid freeform fabrication techniques,
microsphere sintering, and coating [142, 264–266]. A
supercritical gas foaming technique might be used as well
[238, 267, 268].
Apatite-based biocomposites
A biological apatite is known to be the major inorganic
phase of mammalian calcified tissues [21, 22]. Conse-
quently, CDHA, HA, carbonateapatite (both with and
without dopants) and, occasionally, FA have been applied
to prepare biocomposites with other compounds, usually
with the aim to improve the bioactivity. For example, PS
composed with HA can be used as a starting material for
long-term implants [269–271]. Retrieved in vivo, HA/PS
biocomposite-coated samples from rabbit distal femurs
demonstrated direct bone apposition to the coatings, as
compared with the fibrous encapsulation that occurred
when uncoated samples were used [269]. The resorption
time of such biocomposites is a very important factor,
which depends on polymer’s microstructure and the pres-
ence of modifying phases [270].
Various apatite-containing biocomposites with PVA
[255, 272–278], polyvinyl alcohol phosphate (PVAP)
[280], and several other polymeric components [279, 281–
292] have already been developed. Namely, PVA/CDHA
biocomposite blocks were prepared by precipitation of
CDHA in aqueous solutions of PVA [255]. An artificial
cornea consisted of a porous nano-HA/PVA hydrogel skirt
and a transparent center of PVA hydrogel has been
prepared as well. The results displayed a good biocom-
patibility and interlocking between artificial cornea and
host tissues [276, 277]. PVAP has been chosen as a poly-
mer matrix, because its phosphate groups can act as a
coupling/anchoring agent, which has a higher affinity
toward the HA surface [280]. Greish and Brown [283–285]
developed HA/Ca poly(vinyl phosphonate) biocomposites.
A template-driven nucleation and mineral growth process
for the high-affinity integration of CDHA with polyhydr-
oxyethyl methacrylate (PHEMA) hydrogel scaffold have
been developed as well [292].
Polyetheretherketone (PEEK) [177, 179, 293–299] and
high-impact polystyrene [300] were applied to create bio-
composites with HA having a potential for clinical use in
load-bearing applications. The study on reinforcing PEEK
with thermally sprayed HA particles revealed that the
mechanical properties increased monotonically with the
reinforcement concentration, with a maximum value in the
study of 40% volume fraction of HA particles [295–297].
The reported ranges of stiffness within 2.8–16.0 GPa and
strength within 45.5–69 MPa exceeded the lower values
for human bone (7–30 GPa and 50–150 MPa, respectively)
[296]. Modeling of the mechanical behavior of HA/PEEK
biocomposites is available elsewhere [298].
Biodegradable poly(a-hydroxyesters) are well estab-
lished in clinical medicine. Currently, they provide with a
good choice when a suitable polymeric filler material is
sought. For example, HA/PLGA composites were devel-
oped, which appeared to possess a cellular-compatibility
suitable for bone tissue regeneration [301–308]. Zhang and
Ma [48, 233] seeded highly porous PLLA foams with HA
particles in order to improve the osteoconductivity of
polymer scaffolds for bone tissue engineering. They pointed
out that hydration of the foams prior to incubation in sim-
ulated body fluid increased the amount of carbonated CDHA
material due to an increase in COOH and OH groups on the
polymer surface, which apparently acted as nucleation sites
for apatite. The following values of Young’s modulus,
compressive, bending, and tensile strengths for PLLA/HA
composites have been achieved: 5–12 GPa, 78–137 MPa,
44–280 MPa, and 10–30 MPa, respectively [309]. How-
ever, these data do not appear to be in a good agreement with
HA/PLLA biocomposite unit cell model predictions [310].
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On their own, PGA and PLA are known to degrade
to acidic products (glycolic and lactic acids, respectively)
that both catalyze polymer degradation and cause inflam-
matory reactions of the surrounding tissues [311]. Thus,
in biocomposites of poly(a-hydroxyesters) with calcium
orthophosphates, the presence of slightly basic compounds
(HA, TTCP) to some extent neutralizes the acid molecules,
provides with a weak pH-buffering effect at the polymer
surface and, therefore, more or less compensates these
drawbacks [137, 312–314]. However, additives of even
more basic chemicals (e.g., CaO, CaCO3) might be nec-
essary [142, 313, 315, 316]. Extensive cell culture
experiments on pH-stabilized composites of PGA and
carbonateapatite were reported, which afterwards were
supported by extensive in vitro pH-studies [317]. A con-
sequent development of this approach has led to designing
of functionally graded composite skull implants consisting
of polylactides, carbonateapatite, and CaCO3 [318, 319].
Besides the pH-buffering effect, inclusion of calcium or-
thophosphates was found to modify both surface and bulk
properties of the biodegradable poly(a-hydroxyesters) by
increasing the hydrophilicity and water absorption of the
polymer matrix, thus altering the scaffold degradation
kinetics. For example, polymer biocomposites filled with
HA particles was found to hydrolyze homogeneously due
to water penetrating into interfacial regions [320].
Biocomposites of poly(a-hydroxyesters) with calcium
orthophosphates are mainly prepared by incorporating the
inorganic phase into a polymeric solution, followed by
drying under vacuum. The resulting solid composites might
be shaped using different processing techniques. One can
also prepare these biocomposites by mixing HA particles
with L-lactide prior the polymerization [312] or by a
combination of slip-casting technique and hot-pressing
[321]. A surfactant might be useful to keep the suspension
homogeneity [322]. Besides, HA/PLA [251, 252] and HA/
PLGA [253] microspheres might be prepared by a micro-
emulsion technique. More complex carbonated-FA/PLA
porous biocomposite scaffolds are also known [323]. An
interesting list of references, assigned to the different ways
of preparing HA/poly(a-hydroxyesters) biodegradable
composites, might be found in publications by Durucan and
Brown [49, 324, 325]. The authors prepared CDHA/PLA
and CDHA/PLGA composites by solvent casting technique
with a subsequent hydrolysis of a-TCP to CDHA in
aqueous solutions. The presence of both polymers was
found to inhibit a-TCP hydrolysis, if compared with that of
single-phase a-TCP; what is more, the inhibiting effect of
PLA exceeded that of PLGA [49, 324, 325]. The physical
interactions between calcium orthophosphates and poly(a-
hydroxyesters) might be easily seen in Fig. 1 [49]. Nev-
ertheless, it should not be forgotten that typically non-melt-
based routes lead to the development of composites with
lower mechanical performance and many times require the
use of toxic solvents and intensive hand labor [146].
The mechanical properties of poly(a-hydroxyesters)
could be substantially improved by the addition of cal-
cium orthophosphates [326, 327]. Shikinami and Okuno
[137] developed CDHA/PLLA composites of very high
mechanical properties; mini-screws and mini-plates made
of these composites have been manufactured and tested
[320]. They have shown easy handling and shaping
according to the implant site geometry, total resorbability,
good ability to bond directly to the bone tissue without
Fig. 1 SEM micrographs
of a a-TCP compact;
b a-TCP-PLGA biocomposite
(bars = 5 lm). Reprinted from
Ref. [49] with permission
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interposed fibrous tissue, osteoconductivity, biocompati-
bility and high stiffness retainable for the period necessary
to achieve bone union [320]. The initial bending strength of
280 MPa exceeded that of cortical bone (120–210 MPa),
while the modulus was as high as 12 GPa [137]. The
strength could be maintained above 200 MPa up to
25 weeks in phosphate-buffered saline solution. Such bio-
composites were obtained from precipitation of a PLLA/
dichloromethane solution, where small granules of uni-
formly distributed CDHA microparticles (average size of
3 lm) could be prepared [136]. Porous scaffolds of poly-
DL-lactic acid (PDLLA) and HA have been manufactured
as well [268, 328, 329]. Upon implantation into rabbit
femora, a newly formed bone was observed and biodeg-
radation was significantly enhanced if compared with
single-phase HA bioceramics. This might be due to a local
release of lactic acid, which in turn dissolves HA. In other
studies, PLA and PGA fibers were combined with porous
HA scaffolds. Such reinforcement did not hinder bone
ingrowth into the implants, which supported further
development of such biocomposites as bone graft substi-
tutes [47, 48, 309, 330, 331].
Recently, blends (named as SEVA-C) of ethylene-vinyl
alcohol copolymer (EVOH) with starch filled with 10–
30 wt% HA have been fabricated to yield biocomposites
with modulus up to *7 GPa with a 30% HA loading [332–
337]. The incorporation of bioactive fillers such as HA in
SEVA-C aimed to assure the bioactive behavior of the
composite and to provide the necessary stiffness within the
typical range of human cortical bone properties. These
biocomposites exhibited a strong in vitro bioactivity that
was supported by the polymer’s water-uptake capability
[338]. However, the reinforcement of SEVA-C by HA
particles was found to affect the rheological behavior of the
blend. A degradation model of these biocomposites is
available [339].
Higher homologues poly(3-hydroxybutyrate), 3-PHB,
and poly(3-hydroxyvalerate), 3-PHV, show almost no
biodegradation. Nevertheless, biocomposites of these
polymers with calcium orthophosphates showed a good
biocompatibility both in vitro and in vivo [94, 340–345].
Both bioactivity and mechanical properties of these bio-
composites can be tailored by varying the volume
percentage of calcium orthophosphates. Similarly, bio-
composites of poly(hydroxybutyrate-co-hydroxyvalerate)
(PHBHV) with both HA and amorphous carbonated apatite
(almost ACP) appeared to have a promising potential for
repair and replacement of damaged bones [346–349].
Along this line, PCL is used as a slowly biodegradable, a
but well-biocompatible polymer. PCL/HA composites have
been already discussed as suitable materials for substitu-
tion, regeneration, and repair of bone tissues [264, 350–
357]. For example, biocomposites were obtained by
infiltration of e-caprolactone monomer into porous apatite
blocks and in situ polymerization [353]. The composites
were found to be biodegradable and might be applied as
cancellous or trabecular bone replacement material or for
cartilage regeneration. Both the mechanical performance
and biocompatibility in osteoblast cell culture of PCL were
shown to be strongly increased when HA was added [358].
Several preparation techniques of PCL/HA composites are
known. For example, to make composite fibers of PCL/
nano-HA, the desired amount of nano-HA powder was
dispersed in a solvent using magnetic stirrer followed by
ultrasonication for 30 min. Then, PCL was dissolved in this
suspension, followed by the solvent evaporation [359]. The
opposite preparation order is also possible: PCL was ini-
tially dissolved in chloroform at room temperature (7–10%
weight/volume), then HA (*10 lm particle size) was
suspended in the solution, sonicated for 60 s, followed by
the solvent evaporation [129] or salt-leaching [360]. The
mechanical properties obtained by this technique were
about one-third that of trabecular bone. In a comparative
study, PCL and biological apatite were mixed in the ratio
19:1 in an extruder [361]. At the end of the preparation, the
mixture was cooled in an atmosphere of nitrogen. The
authors observed that the presence of biological apatite
improved the modulus while concurrently increasing the
hydrophilicity of the polymeric substrate. Besides, an
increase in apatite concentration was found to increase both
the modulus and yield stress of the composite, which
indicated to good interfacial interactions between the bio-
logical apatite and PCL. It was also observed that the
presence of biological apatite stimulated osteoblasts
attachment to the biomaterial and cell proliferation [361].
In another study, a PCL/HA biocomposite was prepared by
blending in melt form at 120 C until the torque reached
equilibrium in the rheometer that was attached to the
blender [362]. Then the sample was compression-molded
and cut into specimens of appropriate size for testing. It
was observed that the composite containing 20 wt% HA
had the highest strength [362]. However, a direct grafting
of PCL on the surface of HA particles seems to be the most
interesting preparation technique [350]. HA porous scaf-
folds were coated by a PCL/HA composite coating [50]. In
this system, PCL, as a coating component, was able to
improve the brittleness and low strength of the HA scaf-
folds, whereas the particles in the coating were to improve
the osteoconductivity and bioactivity of the coating layer.
More complex PDLLA/PCL/HA biocomposites have been
prepared as well [363]. Further details on both PCL/HA
biocomposites and processing methodologies thereof might
be found elsewhere [264].
The spread of attached human osteoblasts onto PLA and
PCL films reinforced with CDHA and sintered HA was
shown to be higher than for the polymers alone [152].
J Mater Sci (2009) 44:2343–2387 2355
123
Moreover, biochemical assays relating cell activity to DNA
content allowed concluding that cell activity was more
intense for the composite films [152]. Kim et al. [50]
coated porous HA blocks with PCL from dichloromethane
solution and performed drug-release studies. The antibiotic
tetracycline hydrochloride was added into this layer,
yielding a bioactive implant with drug release for longer
than a week.
Yoon et al. [364] investigated the highest mechanical
and chemical stability of FA by preparing FA/collagen
biocomposites and studied their effect in osteoblast-like
cell culture. The researchers found an increased cellular
activity in FA composites compared with HA composites.
This finding was confirmed in another study by means of
variations in the fluoride content for FA-HA/PCL com-
posites [365]. An interesting phenomenon of fractal growth
of FA/gelatin composite crystals (Fig. 2) was achieved by
diffusion of calcium- and orthophosphate ? fluoride-solu-
tions from the opposite sides into a tube filled with a gelatin
gel [366–374]. The reasons of this phenomenon are not
quite clear yet; besides, up to now nothing has yet been
reported on a possible biomedical application of such very
unusual structural composites.
TCP-based biocomposites
Both a-TCP and b-TCP have a higher solubility than HA
(Table 3). Besides, they are faster resorbed in vivo.5
Therefore, these calcium orthophosphates were used
instead of HA to prepare completely biodegradable bio-
composites [376–394]. For example, a biodegradable and
osteoconductive biocomposite made of b-TCP particles
and gelatin was proposed [385]. This material was tested in
vivo with good results. It was found to be biocompatible,
osteoconductive, and biodegradable with no need for a
second surgical operation to remove the device after
healing occurred. Herbal extracts might be added to this
biocomposite [386]. Another research group prepared
biocomposites of crosslinked gelatin with b-TCP; they
found both a good biocompatibility and bone formation
upon subcutaneous implantation in rats [387]. Yang et al.
[392] extended this to porous (porosity about 75%) b-TCP/
gelatin biocomposites those also contained BMP-4.
Besides, cell-compatible and possessive some osteoinduc-
tive properties porous b-TCP/alginate-gelatin hybrid
scaffolds were prepared and successfully tested in vitro
[389]. More to the point, biocomposites of b-TCP with
PLLA [382, 383] and copolyester lactide-co-glycolide-co-
e-caprolactone [384] were prepared. Although b-TCP was
able to counter the acidic degradation of the polyester to
some extent, it did not prevent a pH drop down to *6.
Nevertheless, implantation of this biocomposite in beagles’
mandibular bones was successful [384].
Based on the self-reinforcement concept, biocomposites
of TCP with polylactides were prepared and studied using
conventional mechanical testing [395]. Bioresorbable
scaffolds were fabricated from such biocomposites [396].
Chitosan was also used as the matrix for the incorporation
of b-TCP by a solid/liquid phase separation of the polymer
solution and subsequent sublimation of the solvent. Due to
complexation of the functional groups of chitosan with
calcium ions of b-TCP, these biocomposites had a better
compressive modulus and strength [397]. PCL/b-TCP
biocomposites were developed as well [398–401] and their
in vitro degradation behavior was systematically monitored
by immersion in simulated body fluid at 37 C [400]. To
extend this topic further, the PCL/b-TCP biocomposites
might be loaded by drugs [401].
Cell culture tests on b-TCP/PLLA biocomposites were
reported; the biocomposites showed no cytotoxicity and
evidenced good cell attachment to its surface [376]. An in
vitro study with primary rat calvarial osteoblasts showed an
increased cellular activity in the BMP-loaded samples
[392]. Other researchers investigated BMP-2-loaded por-
ous b-TCP/gelatin biocomposites (porosity 95%, average
pore size 180–200 lm) [402] and confirmed the precious
study. Biocomposites of b-TCP and glutaraldehyde cross-
linked gelatin were manufactured and tested in vitro to
measure the material cytotoxicity [388]. The experimental
results revealed that the amount of glutaraldehyde cross-
linking agent should be less than 8% to decrease the
toxicity on the osteoblasts and to avoid inhibition of cel-
lular growth caused by the release of residual or
uncrosslinked glutaraldehyde.
Fig. 2 A biomimetically grown aggregate of FA that was crystallized
in a gelatin matrix. Its shape can be explained and simulated by a
fractal growth mechanism. Scale bar: 10 lm. Reprinted from Ref.
[366] with permission
5 However, there are some reports about a lack of TCP biodegra-
dation after implantation in calvarial defects [375].
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A long-term implantation study of PDLLA/a-TCP
composites in a loaded sheep implant model showed good
results after 12 months, but a strong osteolytic reaction
after 24 months. This was ascribed to the almost complete
dissolution of a-TCP to this time and an adverse reaction of
the remaining PDLLA [403].
More complex calcium orthophosphate-based biocom-
posites are known as well. For example, there is a
composite consisting of three interpenetrating networks:
TCP, CDHA, and PLGA [404]. Firstly, a porous TCP
network was produced by coating a polyurethane foam by
hydrolysable a-TCP slurry. Then, a CDHA network was
derived from a calcium orthophosphate cement filled in the
porous TCP network. Finally, the remaining open pore
network in the CDHA/a-TCP structures was infiltrated with
PLGA. This biocomposite consists of three phases with
different degradation behavior. It was postulated that bone
would grow on the fastest degrading network of PLGA,
while the remaining calcium orthophosphate phases would
remain intact thus maintaining their geometry and load-
bearing capability [404].
Other calcium orthophosphate-based biocomposites
The number of research papers devoted to biocomposites
based on other calcium orthophosphates is substantially
lesser than those devoted to apatites and TCP. Biphasic
calcium phosphate (BCP)6 appears to be the most popular
among the remaining calcium orthophosphates. Collagen-
coated BCP ceramics was studied and the biocompatibility
toward osteoblasts was found to increase upon coating with
collagen [405]. Another research group created porous
PDLLA/BCP scaffolds and coated them with a hydrophilic
PEG/vancomycin composite for both drug-delivery pur-
poses and surface modification [406]. More to the point,
PLGA/BCP composites were fabricated [407, 408] and
their cytotoxicity and fibroblast properties were found to be
acceptable for natural bone tissue reparation, filling, and
augmentation [409, 410]. PCL/BCP biocomposites are
known as well [411].
A choice of DCPD-based biocomposites of DCPD,
albumin, and duplex DNA was prepared by water/oil/water
interfacial reaction method [250]. Core-shell type DCPD/
chitosan biocomposite fibers were prepared by a wet
spinning method in another study [412]. The energy-dis-
persive X-ray spectroscopy analysis indicated that Ca and
P atoms were mainly distributed on the outer layer of the
composite fibers; however, a little amount of P atoms
remained inside the fibers. This indicated that the com-
posite fibers formed a unique core-shell structure with shell
of calcium orthophosphate and core of chitosan [412].
Although, this is not to the point, it is interesting to mention
that some DCPD/polymer composites could be used as
proton conductors in battery devices [413, 414]. Nothing
has been reported on their biocompatibility but, perhaps,
sometime the improved formulations will be used to fab-
ricate biocompatible batteries for implantable electronic
devices.
Various ACP-based biocomposites for dental applica-
tions were developed [415–418]. Besides, several ACP-
based formulations were investigated as potential bio-
composites for bone grafting [349, 419–421]. Namely,
ACP/PPF biocomposites were prepared by in situ precipi-
tation [420], while PHB/carbonated ACP and PHBHV/
carbonated ACP biocomposites appeared to be well suited
as slowly biodegradable bone substitution material [349].
Another example comprises hybrid nano-capsules of *50–
70 nm in diameter which were fabricated by ACP miner-
alization of shell crosslinked polymer micelles and
nanocages [421]. These nano-capsules consisted of a con-
tinuous ultrathin inorganic surface layer that infiltrated the
outer crosslinked polymeric domains. They might be used
as structurally robust, pH-responsive biocompatible hybrid
nanostructures for drug delivery, bioimaging, and thera-
peutic applications [421].
Calcium orthophosphate cement-based biocomposites
and concretes
Inorganic self-setting calcium orthophosphate cements,
which harden in the body, were introduced by LeGeros
et al. [422] and Brown and Chow [423, 424] in the early
1980s.7 Since then, these cements have been broadly
studied and many formulations have been proposed [427].
The cements set and harden due to various chemical
interactions among calcium orthophosphates that finally
lead to formation of a monolithic body consisting of either
CHDA or DCPD with possible admixtures of other phases.
Unfortunately, having the ceramic nature, calcium ortho-
phosphate cements are brittle after hardening and the
setting time is sometimes unsuitable for clinical procedures
[427]. Therefore, various attempts have been performed to
transform the cements into biocomposites, e.g., by adding
hydroxylcarboxylic acids, to control the setting time [428],
gelatin to improve both the mechanical properties and the
setting time [391, 429–431] or osteocalcin/collagen to
increase the bioactivity [432]. More to the point, various
reinforcement additives of different shapes and nature are
6 BCP is a solid composite of HA and b-TCP; however, similar
composites of HA and a-TCP are possible as well [23].
7 There is an opinion [425] that the self-setting calcium orthophos-
phate cements for orthopedic and dental restorative applications have
first been described in the early 1970s by Driskell et al. [426] in US
Patent No. 3913229.
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widely used to improve the mechanical properties of cal-
cium orthophosphate cements [427]. Even carbon
nanotubes were used for this purpose [433]! Although the
biomaterials community does not use this term, a sub-
stantial amount of the reinforced cement formulations
might be defined as calcium orthophosphate-based con-
cretes.8 The idea behind the concretes is simple: if a strong
filler is present in the matrix, it might stop crack
propagation.
Various apatite-containing biocomposite formulations
based on PMMA [435–445] and PEMA [94, 446, 447]
have been already developed. Such biocomposites might be
prepared by dispersion of apatite powder into a PMMA
viscous fluid [448] and used for drug-delivery purposes
[449]. When the mechanical properties of the biocomposite
concretes composed of PMMA matrix and HA particles of
various sizes were tested, the tensile results showed that
strength was independent on particle sizes. In addition, up
to 40 wt% HA could be added without impairing the
mechanical properties [438, 439]. After immersion into
Ringer’s solution, the tensile strength was not altered,
whereas the fatigue properties were significantly reduced.
The biocompatibility of PMMA/HA biocomposites was
tested in vivo and enhanced osteogenic properties of the
implants compared with single-phase PMMA were
observed [436, 440–443]. It was shown that not only the
mechanical properties of PMMA were improved but the
osteoblast response of PMMA was also enhanced with the
addition of HA [440]. Thereby, by adding calcium ortho-
phosphates, a non-biodegradable PMMA was made more
bioactive and osteoconductive, yielding a well-processable
biocomposite concrete. As a drawback, the PMMA/HA
formulations possess a low flexural, compressive, and
tensile strength.
A biocomposite made from HA granules and bis-phe-
nol-a-glycidylmethacrylate-based resin appeared to possess
comparable mechanical and biological properties to typical
PMMA cement, leading to potential uses for implant fix-
ation [450]. In order to improve the mechanical properties
of calcium orthophosphate cements and stabilize them at
the implant site, various researchers have resorted to for-
mulations that set in situ, primarily through crosslinking
reactions of the polymeric matrix. For example, TTCP was
reacted with polyacrylic acid (PAA), forming a crosslinked
CDHA/calcium polyacrylate biocomposite [451]. In aque-
ous solutions, TTCP hydrolyzes to CDHA [23] and the
liberated calcium cations react with PAA, forming the
crosslinked network [451]. Reed et al. [452] synthesized a
dicarboxy polyphosphazene that can be crosslinked by
calcium cations and cement-based (TTCP ? DCPD)
CDHA/polyphosphazene biocomposites with a compres-
sive strength *10 MPa and of *65% porosity were
prepared as a result. To mimic PMMA cements, PFF/
b-TCP biocomposites were prepared with the addition of
vinyl monomer to crosslink PPF. As a result, quick setting
and degradable biocomposite cements with a low-heat
output and compressive strengths in the range of 1 to
12 MPa were prepared by varying the molecular weight of
PPF, as well as the contents of the monomer, b-TCP, ini-
tiator, and porogen (NaCl) [453, 454]. An acrylic cement
with Sr-containing HA as a filler [110] and an injectable
polydimethylsiloxane/HA cement [455] have been pre-
pared as well.
In order to improve the mechanical properties of cal-
cium orthophosphate cements, numerous researchers
blended various polymers with the cements. For example,
gelatin might be added to calcium orthophosphate cement
formulations, primarily to stabilize the paste in aqueous
solution before it develops adequate rigidity and, secondly,
to improve the compressive strength [391, 429, 456].
Adding rod-like fillers to the cement formulations also
caused an improvement in the mechanical properties [456].
For example, PAA and PVA were successfully used to
improve the mechanical properties of a TTCP ? DCPD
cement but, unfortunately, with an inevitable and unac-
ceptable reduction of both workability and setting time
[457, 458]. Similar findings were reported in the presence
of sodium alginate and sodium polyacrylate [459]. Other
polymers, such as polyphosphazene, might be used as well
[460–462]. Other examples of polymer/calcium ortho-
phosphate cement formulations might be found elsewhere
[463, 464].
Porous calcium orthophosphate scaffolds with inter-
connected macropores (*1 mm), micropores (*5 lm),
and of high porosity (*80%) were prepared by coating
polyurethane foams with a TTCP ? DCPA cement, fol-
lowed by firing at 1200 C. In order to improve the
mechanical properties of the scaffolds, the open micropores
of the struts were then infiltrated by a PLGA solution to
achieve an interpenetrating bioactive ceramic/biodegrad-
able polymer composite structure. The PLGA-filled struts
were further coated with a 58S bioactive glass/PLGA
composite coating. The obtained complex porous bio-
composites could be used as tissue engineering scaffolds
for low-load-bearing applications [465]. A more compli-
cated construction, in which the PLGA macroporous phase
has been reinforced with a bioresorbable TTCP ? DCPA
cement, followed by surface coating of the entire construct
by a non-stoichiomentic CDHA layer, has been designed as
8 According to Wikipedia, the free encyclopedia: ‘‘Concrete is a
construction material that consists of a cement (commonly Portland
cement), aggregates (generally gravel and sand) and water. It
solidifies and hardens after mixing and placement due to a chemical
process known as hydration. The water reacts with the cement, which
bonds the other components together, eventually creating a stone-like
material’’ [434].
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well [466]. The latter approach has culminated in a unique,
three-phase biocomposite that is simple to fabricate,
osteoconductive, and completely biodegradable.
A porosity level of 42 to 80% was introduced into calcium
orthophosphate cement/chitosan biocomposites by the
addition of the water-soluble mannitol [467]. Chitosan sig-
nificantly improved the mechanical strength of the entire
biocomposite [468]. A similar approach was used by other
researchers who studied the effect of the addition of PLGA
microparticles [469–472] (which can also be loaded with
drugs or growth factors [473–475]) to calcium orthophos-
phate cements. These biocomposites were implanted into
cranial defects of rats and a content of *30 wt% of the
microparticles was found to give the best results [469], while
the addition of a growth factor to the biocomposites signif-
icantly increased bone contact at 2 weeks and enhanced new
bone formation at 8 weeks [475]. The in vivo rabbit femur
implant tests showed that PLGA/calcium orthophosphate
cement formulations exhibited outstanding biocompatibility
and bioactivity, as well as a better osteoconduction and de-
gradability than pure calcium orthophosphate cements [470].
Further details on calcium orthophosphate cement-based
biocomposites and concretes might be found in Ref. [427,
chapter ‘‘Reinforced calcium orthophosphate cements’’].
Nano-calcium orthophosphate-based biocomposites
and nano-biocomposites
Nanophase materials are the materials that have grain sizes
under *100 nm. They have different mechanical and
optical properties if compared with the large-grained
materials of the same chemical composition. Namely,
nanophase materials have the unique surface properties,
such as an increased number of atoms, grain boundaries,
and defects at the surface, huge surface area and altered
electronic structure, if compared with the conventional
micron-sized materials. For example, nano-HA (size
*67 nm) has a higher surface roughness of 17 nm if
compared with 10 nm for the conventional submicron size
HA (*180 nm), while the contact angles (a quantitative
measure of the wetting of a solid by a liquid) are signifi-
cantly lower for nano-HA (6.1) if compared with the
conventional HA (11.51). Additionally, the diameter of
individual pores in a nano-HA compact is five times
smaller (pore diameter *6.6 A˚) than that in the conven-
tional grain-sized HA compacts (pore diameter within
19.8–31.0 A˚) [476–478]. Besides, nano-HA promotes
osteoblast cells adhesion, differentiation, and proliferation,
osteointegration and deposition of calcium containing
minerals on its surface better than microcrystalline HA;
thus enhancing formation of a new bone tissue within a
short period [476–478]. More to the point, nano-HA was
found to cause apoptosis of the leukemia P388 cells [479].
Composites of two or more materials, in which at least
one of the materials is of a nanometer-scale, are defined as
nanocomposites [32]. Natural bone mineral is a hierarchical
nanocomposite of biological origin, because it consists of
nano-sized blade-like crystals of biological apatite grown in
intimate contact with an organic matrix rich in collagen
fibers and organized in a complicated hierarchical structure
[21, 22, 38]. Given the fact that the major organic phase of
bone is collagen, i.e., a natural polymer (Table 1), it is
obvious that a composite of a nanophase calcium ortho-
phosphate with a biodegradable polymer should be
advantageous as bone substitution material. The inorganic
nanophase would be responsible for the mechanical strength
(hardness) and bioactivity, while the polymer phase would
provide the elasticity. In addition, the solubility of calcium
orthophosphates depends on their crystallite size (smaller
crystals have a higher solubility) and on their carbonate
content (higher carbonate content increases the solubility)
[480]. To the author’s best knowledge, among calcium
orthophosphates listed in Table 3, before very recently only
apatites (CDHA, HA and, perhaps, FA) have been available
in the nanocrystalline state. However, very recently, nano-
DCPA [481–483] and nano-MCPM [484] have been syn-
thesized and applied to prepare nano-biocomposites with
strong ionic release to combat tooth caries.
A number of investigations have been conducted recently
to determine the mineralization, biocompatibility, and
mechanical properties of the nano-biocomposites based on
various (bio)polymers and nano-HA.9 These studies covered
nano-HA/PLA [268, 485–492] and its copolymer with PGA
[493–495], nano-HA/collagen [496–508], nano-HA/colla-
gen/PLA [508–516], nano-HA/collagen/PVA [517], nano-
HA/collagen/alginate [518, 519], nano-HA/gelatin [520–
525], nano-HA/poly(hexamethylene adipamide) [526],
nano-HA/PPF [527], nano-HA/polyamide [528–539], nano-
HA/PVA [276, 277, 540–542], nano-HA/PVAP [280],
nano-HA/poly(ethylene-co-acrylic) acid [543, 544], nano-
HA/chitosan [545–548], nano-HA/konjac glucomannan/
chitosan [549], nano-HA/PHEMA/PCL [550], nano-HA/
PCL [322, 359, 551, 552], nano-HA/Ti [553, 554], PCL
semi-interpenetrating nanocomposites [555], and many
other biocompatible hybrid formulations [223, 257, 271,
347, 556–574]. Several nano-biocomposites were found to
be applicable as carriers for growth factors delivery [34, 575,
576]. Besides, the data are available on the excellent bio-
compartibility of such nano-biocomposites [507]. The
dispersion state of nanoparticles appears to be the critical
parameter in controlling the mechanical properties of
9 Unfortunately, in the majority of the already published papers it
often remained unclear whether ‘‘nano-HA’’ represented the stoichi-
ometric nano-HA or a non-stoichiometric nano-CDHA.
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nano-biocomposites, as nanoparticles always tend to
aggregate owing to their high surface energy [347].
Porous (porosity *85%) biocomposites of nano-HA
with collagen and PLA have been prepared by precipitation
and freeze-drying; the nano-biocomposites did not show a
pH drop upon in vitro degradation [509–511]. They were
implanted in the radius of rabbits and showed a high bio-
compatibility and partial resorption after 12 weeks. Nano-
HA/chitosan biocomposites with improved mechanical
stability were prepared from HA/chitosan nanorods [577].
Nano-HA/PLLA biocomposites of high porosity (*90%)
were prepared using thermally induced phase separation
[578]. Besides, nano-HA was used to prepare biocompos-
ites with PAA and the nanostructure of the resulting
nanocrystals exhibited a core-shell configuration [579,
580].
Nano-HA crystals appeared to be suitable for intraos-
seous implantation and offered a potential to formulate
enhanced biocomposites for clinical applications [581].
Thus, the biocompatibility of chitosan in osteoblast cell
culture was significantly improved by addition of nano-HA
[582]. Similar finding is valid for nano-HA/polyamide
biocomposites [531]. Further details on nano-HA-based
biocomposites might be found in an excellent review [32].
More to the point, a more general review on nanobioma-
terial applications in orthopedics is also available [583],
where the interested readers are referred.
Biocomposites with collagen
The main constituent of the bioorganic matrix of bones is
type I collagen10 (Table 1) with molecules about 300 nm in
length. This protein is conducive to crystal formation in the
associated inorganic matrix. It is easily degraded and re-
sorbed by the body and allows good attachment to cells.
Collagen alone is not effective as an osteoinductive
material, but it becomes osteoconductive in combination
with calcium orthophosphates [585]. Both collagen type I
and HA were found to enhance osteoblast differentiation
[586] but combined together, they were shown to accel-
erate osteogenesis. However, this tendency is not so
straightforward: the data are available that implanted HA/
collagen biocomposites enhanced regeneration of calvaria
bone defects in young rats but postponed the regeneration
of calvaria bone in aged rats [587]. Finally, the addition of
calcium orthophosphates to collagen sheets was found to
give a higher stability and an increased resistance to 3D
swelling compared with the collagen reference [588].
Therefore, a bone-analogue based on these two constituents
should possess the remarkable properties. Furthermore, the
addition of bone marrow constituents gives osteogenic and
osteoinductive properties to calcium orthophosphate/col-
lagen biocomposites [1].
The unique characteristics of bones are the spatial ori-
entation between the calcium orthophosphate nanophase
and collagen macromolecules at the nanolevel [35], where
nanocrystals (about 50-nm-length) of biological apatite are
aligned parallel to the collagen fibrils [21, 22, 31, 38],
which is believed to be the source of the mechanical
strength of bones. The collagen molecules and the nano-
crystals of biological apatite assembled into mineralized
fibrils are approximately 6-nm-diameter and 300-nm-long
[31, 35, 38, 510, 589]. Although the complete mechanisms
involved in the bone building strategy are still unclear, the
strengthening effect of apatite nanocrystals in calcified
tissues might be explained by the fact that the collagen
matrix is a load transfer medium and thus transfers the load
to the intrinsically rigid inorganic nanocrystals. Further-
more, nanocrystals of biological apatite located in between
tangled fibrils crosslink the fibers either through a
mechanical interlocking or by forming calcium ion bridges,
thus increasing deformation resistance of the collagenous
fiber network [590].
When calcium orthophosphates are combined with col-
lagen in a laboratory, the biocomposites appear to be
substantially different from natural bone tissue due to a
lack of real interaction between the two components, i.e.,
interactions that are able to modify the intrinsic charac-
teristics of the singular components themselves. The main
characteristics of the route, by which the mineralized hard
tissues are formed in vivo, are that the organic matrix is
laid down first and the inorganic reinforcing phase grows
within this organic matrix [21, 22, 31, 38]. Although to
date, neither the elegance of the biomineral assembly
mechanisms nor the intricate composite nano-architectures
have been duplicated by non-biological methods, the best
way to mimic bone is to copy the way it is formed, namely
by nucleation and growth of CDHA nanocrystals from a
supersaturated solution both onto and within the collagen
fibrils [591–593]. Such syntheses were denoted as ‘‘bio-
logically inspired’’ which means they reproduce an ordered
pattern and an environment very similar to natural ones
[594–596]. The biologically inspired biocomposites of
collagen and calcium orthophosphates (mainly, apatites)
for bone substitute have a long history [29, 364, 499, 597–
615] and started from the pioneering study by Mittelmeier
and Nizard [616], who mixed calcium orthophosphate
granules with a collagen web. Such combinations were
found to be bioactive, osteoconductive, osteoinductive [29,
585, 617–619] and, in general, artificial grafts manufac-
tured from this type of the biocomposites are likely to
behave similarly to bones and be of more use in surgery
10 The structural and biochemical properties of collagens have been
widely investigated and over 25 collagen subtypes have been
identified [584].
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than those prepared from any other materials. Indeed, some
data are available on the superiority of calcium ortho-
phosphate/collagen biocomposite scaffolds over the artifi-
cial polymeric and calcium orthophosphate bioceramic
scaffolds individually [620].
It has been found that calcium orthophosphates may be
successfully precipitated onto a collagen substrate of
whatever form or source [29, 36, 499, 621, 622]. However,
adherence of calcium orthophosphate crystals to collagen
did depend on how much the collagen had been denatured:
the more fibrillar the collagen, the greater attachment.
Clarke et al. [602] first reported the production of a bio-
composite produced by precipitation of DCPD onto a
collagen matrix with the aid of phosphorylated amino acids
commonly associated with fracture sites. Apatite cements
(DCPD ? TTCP) have been mixed with a collagen sus-
pension, hydrated, and allowed to set. CDHA crystals were
found to nucleate on the collagen fibril network, giving a
material with the mechanical properties weaker than those
reported for bone. More to the point, these biocomposites
were without the nanostructure similar to that of bone [599,
623]. The oriented growth of OCP crystals on collagen was
achieved by an experimental device in which Ca2? and
PO4
3- ions diffused into a collagen disk from the opposite
directions [622, 624, 625]. Unfortunately, these experi-
ments were designed to simulate the mechanism of in vivo
precipitation of biological apatite only; due to this reason,
the mechanical properties of the biocomposites were not
tested [626].
Conventionally, collagen/calcium orthophosphate bio-
composites can be prepared by blending or mixing of
collagen and calcium orthophosphates, as well as by bio-
mimetic methods [29, 32, 34, 37, 496, 499, 510, 576, 589,
594–596, 599, 621, 627–633]. Besides, collagen might be
incorporated into calcium orthophosphate cements [599,
623, 634]. Typically, the type I collagen sponge is pres-
oaked in PO4
3--containing a highly basic aqueous solution
and then is immersed into a Ca2?-containing solution to
allow mineral deposition. Also, collagen I fibers might be
dissolved in acetic acid and then this solution is added to
phosphoric acid, followed by the neutralization synthesis
(performed at 25 C and solution pH within 9–10) between
an aqueous suspension of Ca(OH)2 and the H3PO4/collagen
solution [594, 595]. In order to ensure the quality of the
final product, it is necessary to control the Ca/P ionic ratio
in the reaction solution. One way to do this is to dissolve a
commercial calcium orthophosphate in an acid; another is
to add Ca2? and PO4
3- ions in a certain ratio to the solu-
tion and after that induce the reaction [35]. Biomimetically,
one can achieve an oriented growth of CDHA crystals onto
dissolved collagen fibrils in aqueous solutions via a self-
organization mechanism [628]. A number of authors pro-
duced calcium orthophosphate/collagen biocomposites by
mixing preformed ceramic particles with a collagen sus-
pension [635–637]. However, in all blended composites,
the crystallite sizes of calcium orthophosphates were not
uniform and the crystals were often aggregated and ran-
domly distributed within a fibrous matrix of collagen.
Therefore, no structural similarity to natural bone was
obtained, and only a compositional similarity to that of
natural bone was achieved. Crystallization of CDHA in
aqueous solutions might be performed in the presence of a
previously dispersed collagen [29, 499]. More to the point,
collagen might be first dispersed in an acidic solution,
followed by addition of calcium and orthophosphate ions
and then coprecipitation of collagen and CDHA might be
induced by either increasing the solution pH or adding
mixing agents [37]. Although it resulted in biocomposites
with poor mechanical properties, pressing of the HA/col-
lagen mixtures at 40 C under 200 MPa for several days is
also known [638]. Attempts have been performed for a
computer simulation of apatite/collagen composite forma-
tion process [639]. It is interesting to note, that collagen/
HA biocomposites were found to possess some piezo-
electric properties [640].
As the majority of the collagen/HA, biocomposites are
conventionally processed by anchoring micro-HA particles
into collagen matrix, it makes quite difficult to obtain a
uniform and homogeneous composite graft. Besides, such
biocomposites have inadequate mechanical properties;
over and above, the proper pore sizes have not been
achieved either. Further, microcrystalline HA, which is in
contrast to nanocrystalline natural bone apatite, might take
a longer time to be remodeled into a new bone tissue upon
the implantation. In addition, some of the biocomposites
exhibited very poor mechanical properties, probably due to
a lack of strong interfacial bonding between the constitu-
ents. The aforementioned data clearly demonstrate that the
chemical composition similar to bone is insufficient for
manufacturing the proper bone grafts; both the mechanical
properties and mimetic of the bone nanostructure are nec-
essary to function as bone in recipient sites. There is a
chance for improving osteointegration by reducing the
grain size of HA crystals by activating ultrafine apatite
growth into the matrix. This may lead to enhance the
mechanical properties and osteointegration with improved
biological and biochemical affinity to the host bone.
Besides, the unidirectional porosity was found to have a
positive influence on the ingrowth of the surrounding tis-
sues into the pores of collagen/HA biocomposites [641].
Bovine collagen might be mixed with HA and such
biocomposites are marketed commercially as bone-graft
substitutes those further can be combined with bone mar-
row aspirated from the iliac crest of the site of the fracture.
Application of these materials was compared with auto-
grafts for the management of acute fractures of long bones
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with defects, which had been stabilized by internal or
external fixation [642, 643]. These biocomposites are
osteogenic, osteoinductive, and osteoconductive; however,
they lack the structural strength and require harvest of the
patient’s bone marrow. Although no transmission of dis-
eases has been recorded yet, the use of bovine collagen
might be a source of concern [2].
Collagen sponges with an open porosity (30–100 lm)
were prepared by a freeze-drying technique and then their
surface was coated by a 10-lm layer of biomimetic apatite
precipitated from simulated body fluid [644]. The
researchers found a good in vitro performance with fibro-
blast cell culture. Collagen/HA microspheres or gel beads
have been prepared in the intention of making injectable
bone fillers [645, 646]. Liao et al. [647] succeeded in
mimicking the bone structure by blending carbonateapatite
with collagen. A similar material (mineralized collagen)
was implanted into femur of rats and excellent clinical
results were observed after 12 weeks [648]. Collagen/HA
biocomposites were prepared and their mechanical per-
formance was increased by crosslinking the collagen fibers
with glutaraldehyde [500, 502, 503]. These biocomposites
were tested in rabbits and showed a good biological per-
formance, osteoconductivity, and biodegradation. A similar
approach was selected to prepare HA/collagen micro-
spheres (diameter *5 lm) by a water–oil emulsion
technique in which the surface was also crosslinked by
glutaraldehyde [646]. That material showed a good in vitro
performance with osteoblast cell culture. A porous bone-
graft substitute was formed from a nano-HA/collagen
biocomposite combined with PLA by a freeze-drying
method; the resulting material was found to mimic natural
bone at several hierarchical levels [510]. Subsequent in
vitro experiments confirmed a good adhesion, proliferation,
and migration of osteoblasts into this composite [509]. A
further increase in biocompatibility might be achieved by
the addition of silicon; thus, to enhance bone substitution,
Si-substituted HA/collagen composites have been devel-
oped with silicon located preferentially in the collagen
phase [501]. Porous (porosity level *95% with intercon-
nected pores of 50–100 lm) biocomposites of collagen
(crosslinked with glutaraldehyde) and b-TCP have been
prepared by a freeze-drying technique, followed by subli-
mation of the solvent; the biocomposites showed a good
biocompatibility upon implantation in the rabbit jaw [649].
Biocomposites of calcium orthophosphates with colla-
gen were found to be useful for drug-delivery purposes
[519, 607, 650–652]. Namely, an HA/collagen–alginate
(20 lL) with the rh-BMP2 (100 lg/mL, 15 lL) showed
bone formation throughout the implant 5 weeks after
implantation without obvious deformation of the material
[519]. Gotterbarm et al. [651] developed a two-layered
collagen/b-TCP implant augmented with chondral inductive
growth factors for the repair of osteochondral defects in the
trochlear groove of minipigs. This approach might be a new
promising option for the treatment of deep osteochondral
defects in joint surgery.
To conclude this part, one should note that biocom-
posites of apatites with collagen are a very hot topic of the
research and up to now, just a few papers are devoted to
biocomposites of other calcium orthophosphates with col-
lagen [651, 653]. These biomaterials mimic natural bones
to some extent, while their subsequent biological evalua-
tion suggests that they are readily incorporated into the
bone metabolism in a way similar to bone remodeling,
instead of acting as permanent implant [510, 616]. Colla-
graft, Bio-Oss, and Healos are the several examples of
the commercially available calcium orthophosphate/colla-
gen bone grafts for clinical use [32]. However, the
performance of these biocomposites depends on the source
of collagen from which it was processed. Several attempts
have been made to simulate the collagen–HA interfacial
behavior in real bone by means of crosslinking agents such
as glutaraldehyde [500, 502, 503, 621, 646, 649] with the
purpose to improve the mechanical properties of these
biocomposites. Unfortunately, a further progress in this
direction is restricted by a high cost, difficulty to control
cross-infection, a poor definition of commercial sources of
collagens, as well as by a lack of an appropriate technology
to fabricate bone-resembling microstructures. Further details
on calcium orthophosphate/collagen composites, including
the list of the commercially available products, might be
found elsewhere [32, 611].
Biocomposites with other bioorganic compounds
and biological macromolecules
Besides collagen, both human and mammalian bodies
contain dozens types of various bioorganic compounds,
proteins, and biological macromolecules. The substantial
amounts of them potentially might be used to prepare
biocomposites with calcium orthophosphates. For example,
a biologically strong adhesion (to prevent invasion of
bacteria) between teeth and the surrounding epithelial tis-
sues is attributed to a cell-adhesive protein, laminin [654].
In order to mimic the nature, a laminin/apatite biocom-
posite layer was successfully created on the surface of both
titanium [655] and EVOH [656, 657] using the biomimetic
approach.
Calcium orthophosphate/gelatin biocomposites are
widely investigated as potential bone replacement bioma-
terials [254, 272–274, 366–374, 385–392, 402, 429–431,
456, 520–525, 658–669]. For example, gelatin foams were
successfully mechanically reinforced by HA and then
crosslinked by a carbodiimide derivative [254]. Such foams
were shown to be a good carrier for antibiotic tetracycline
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[662]. Several biocomposites of calcium orthophosphates
with alginates11 have been prepared [389, 518, 519, 523,
595, 670]. For example, porous HA/alginate composites
based on hydrogels were prepared both biomimetically
[595] and by using a freeze-drying technique [670].
Another research group succeeded in preparation of
biphasic but monolithic scaffolds using a similar prepara-
tion route [671]. Their biocompatibility in cell culture
experiments and in vitro biodegradability were high;
however, a mechanical strength could be better.
Various biocomposites of calcium orthophosphates with
chitosan [239, 397, 412, 419, 435, 467, 545–549, 566, 567,
577, 582, 663, 669, 672–683] and chitin [183, 394, 513,
684–688] are also very popular. For example, a solution-
based method was developed to combine HA powders with
chitin, in which the ceramic particles were uniformly dis-
persed [684, 685]. Unfortunately, it was difficult to obtain
the uniform dispersions. The mechanical properties of the
final biocomposites were not very good; due to a poor
adhesion between the filler and the matrix both the tensile
strength and modulus were found to decrease with the
increase in the HA amount. Microscopic examination
revealed that HA particles were intervened between the
polymer chains, weakening their interactions, and
decreasing the entire strength [684, 685].
Biocomposites of CDHA with water-soluble proteins,
such as bovine serum albumin (BSA), might be prepared
by a precipitation method [463, 689–692]. In such bio-
composites, BSA is not strongly fixed to solid CDHA,
which is useful for a sustained release. However, this is not
the case if a water/oil/water interfacial reaction route has
been used [250]. To extend this subject, inclusion of DNA
into CDHA/BSA biocomposites was claimed [250, 693–
695]. Besides, bionanocomposites of an unspecified cal-
cium orthophosphate with DNA were prepared as well
[696].
Akashi and co-workers [697] developed a procedure to
prepare calcium orthophosphate-based biocomposites by
soaking hydrogels in supersaturated by Ca2? and PO4
3-
ions solutions in order to precipitate CDHA in the hydro-
gels (up to 70 wt% of CDHA could be added to these
biocomposites). This procedure was applied to chitosan;
the 3D shape of the resulting biocomposite was controlled
by the shape of the starting chitosan hydrogel [698].
Another research group developed biocomposites based on
in situ calcium orthophosphate mineralization of self-
assembled supramolecular hydrogels [699].
Various biocomposites of CDHA with glutamic and
aspartic amino acids, as well as poly-glutamic and
poly-aspartic amino acids have been prepared and inves-
tigated by Bigi et al. [279, 281, 700–703]. These
(poly)amino acids were quantitatively incorporated into
CDHA crystals, provoking a reduction of the coherent
length of the crystalline domains and decreasing the
crystal sizes. The relative amounts of the (poly)amino
acid content in the solid phase, determined through HPLC
analysis, increased with their concentration in solution up
to a maximum of about 7.8 wt% for CDHA/aspartic acid
and 4.3 wt% for CDHA/glutamic acid biocomposites. The
small crystal dimensions, which implied a great surface
area, and the presence of (poly)amino acids were sug-
gested to be relevant for possible application of these
biocomposites for hard tissues replacement [279, 281,
700–703].
Recently, BCP (HA ? b-TCP)/agarose macroporous
scaffolds with controlled and complete interconnection,
high porosity, thoroughly open pores, and tailored pore size
were prepared for tissue engineering application [704,
705]. Agarose, a biodegradable polymer, was selected as
the organic matrix, because it was a biocompatible
hydrogel, which acted as gelling agent leading to strong
gels and fast room temperature polymerization. Porous
scaffolds with the designed architecture were manufactured
by combining a low-temperature shaping method with
stereo-lithography and two drying techniques. The bio-
compatibility of this BCP/agarose system was tested with
mouse L929 fibroblast and human Saos-2 osteoblast during
different colonization times [704].
Fibrin sealants are non-cytotoxic, fully resorbable, bio-
logical matrices that simulate the last stages of a natural
coagulation cascade, forming a structured fibrin clot similar
to a physiological clot [706]. Biocomposites of calcium
orthophosphates with fibrin sealants might develop the
clinical applications of bone substitutes. The 3D mesh of
fibrin sealant interpenetrates the macro- and micro-porous
structure of calcium orthophosphate ceramics [9]. The
physical, chemical, and biological properties of calcium
orthophosphate bioceramics and the fibrin glue might be
cumulated in biocomposites, suitable for preparation of
advanced bone grafts [707–718].
Furthermore, there are biocomposites of calcium
orthophosphates with bisphosphonates [719], silk fibroin
(that is a hard protein extracted from silk cocoon) [249,
562–564, 569, 570, 720–725], chitosan ? silk fibroin
[726], fibronectin [727], and casein phosphopeptides [728].
Besides, the reader’s attention is pointed out to an inter-
esting approach to crystallize CDHA inside poly(allyl-
amine)/poly(styrene sulfonate) polyelectrolyte capsules
resulting in empty biocomposite spheres of micron size
[729]. Depending on the amount of precipitated CDHA, the
thickness of the shell of biocomposite spheres can be
varied between 25 and 150 nm. These biocomposite
11 Alginates are a family of unbranched binary copolymers with a
structure comprising 1–4 glycosidically linked b-D-mannuronic acid
and its C-5 epimer a-Lguluronic acid [595].
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capsules might find application as medical agents for bone
repairing and catalytic microreactors [729].
Injectable bone substitutes
IBS represent ready-to-use suspensions of calcium ortho-
phosphate powder(s) in a liquid carrier phase. They look
like viscous pastes with the rheological properties, suffi-
cient to inject them into bone defects by means of surgical
syringes and needles. Usually, the necessary level of vis-
cosity is created by the addition of water-soluble polymers
[104, 730, 731]. Therefore the majority of calcium ortho-
phosphate-based IBS formulations might be considered as
a subgroup of calcium orthophosphate/polymer biocom-
posites. For example, an IBS was described that involved a
silanized hydroxyethylcellulose carrier with BCP, consist-
ing of HA and b-TCP [732]. The suspension is liquid at pH
within 10–12, but gels quickly at pH \ 9. Injectable
composites can be formed with b-TCP to improve
mechanical integrity [453]. Similarly, Bennett et al. [733]
showed that a polydioxanone-co-glycolide-based biocom-
posite reinforced with HA or b-TCP can be used as an
injectable or moldable putty. During the crosslinking
reaction following injection, carbon dioxide is released
allowing the formation of interconnected pores.
Daculsi et al. [84, 731, 734–740] developed viscous IBS
biocomposites based on BCP (60% HA ? 40% b-TCP)
and 2% aqueous solution of hydroxypropylmethylcellulose
(HPMC) that was said to be perfectly biocompatible,
resorbable, and easily fitted bone defects (due to an initial
plasticity). The best ratio BCP/HPMC aqueous solution
was found to be at *65/35 w/w. To extend this subject
further, this type of IBS might be loaded by cells [741] or
by microparticles [742].
The advanced characteristics of IBS come from their
good mechanical properties and biocompatibility and the
ease of tissue regeneration. Although the fabrication of IBS
biocomposites in most cases improved the mechanical
properties of the system and provided the material with
resistance to fluids penetration, these achievements were
limited by the amount of polymer that can be added to the
paste. For instance, Mickiewicz et al. [463] reported that
after a critical concentration (that depended on the type and
molecular weight of the polymer, but was always around
10%), the polymer started forming a thick coating on the
crystal clusters, preventing them from interlocking, origi-
nating plastic flow and, as a consequence, decreasing
mechanical properties. More to the point, Fujishiro et al.
[456] reported a decrease in mechanical properties with
higher amounts of gel, which was attributed to the for-
mation of pores due to leaching of gelatin in solution.
Therefore, it seems that mechanical properties, although
improved by the addition of polymers, are still a limitation
for the application of calcium orthophosphate-based IBS
formulations in load-bearing sites [146].
Biocomposites with glasses, inorganic materials,
and metals
In order to overcome the problem of poor mechanical
properties of calcium orthophosphate bioceramics, suitable
biocomposites of calcium orthophosphates reinforced by
various inorganic materials, glasses, and metals have been
developed. Such biocomposites are mainly prepared by the
common ceramic processing techniques such as thermal
treatment after kneading [743–745], powder slurry coating
[746], and metal–sol mixing [747]. For example, HA was
combined with Bioglass (Novabone Products, Alachua,
FL) [748, 749] and with other glasses [750] to form glass–
ceramics biocomposites. Other reinforcement materials for
calcium orthophosphates are differentiated by either shape
of the fillers, namely, particles [751, 752], platelets [753,
754], whiskers [484, 755, 756], fibers [757–759], or their
chemical composition: zirconia and/or PSZ [250, 743–746,
755, 760–793], alumina [250, 751, 754, 793–802], titania
[307, 747, 752, 803–817], other oxides [818–821], silica
and/or glasses [822–829], wollastonite [171, 830–837],
various metals and alloys [759, 794, 817, 838–851], cal-
cium sulfate [852–854], silicon carbide [756], barium
titanate [855], zeolite [856], and several other materials
[271, 857–859]. All these materials have been added to
calcium orthophosphate bioceramics to improve its reli-
ability. Unfortunately, significant amounts of the rein-
forcing phases are needed to achieve the desired properties
and, as these materials are either bioinert, significantly less
bioactive than calcium orthophosphates or not bioresorb-
able, the ability of the biocomposites to form a stable
interface with bone is poorer if compared with calcium
orthophosphate bioceramics alone. Due to the presence of
bioinert compounds, such formulations might be called
bioinert/bioactive composites [822]. The ideal reinforce-
ment material would impart mechanical integrity to a
biocomposite at low loadings, without diminishing its
bioactivity. As clearly seen from the amount of the refer-
ences, apatite/zirconia biocomposites are most popular
ones among the researchers.
There are several types of HA/glass biocomposites. The
first one is also called bioactive glass–ceramics. A dense
and homogeneous biocomposite was obtained after a heat
treatment of the parent glass, which comprised *38 wt%
oxy-FAP (Ca10(PO4)6(O,F)2) and *34 wt% b-wollastonite
(CaO  SiO2) crystals, 50–100 nm in size in a MgO–CaO–
SiO2 glassy matrix [171, 830–837]. A-W glass–ceramics is
an assembly of small apatite particles effectively reinforced
by wollastonite. The bending strength, fracture toughness,
and Young’s modulus of A-W glass–ceramics are the
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highest among bioactive glass and glass ceramics, enabling
it to be used in some major compression load-bearing
applications, such as vertebral prostheses and iliac crest
replacement. It combines a high bioactivity with the suit-
able mechanical properties [860]. b-TCP/wollastonite
biocomposites are also known [861–863]. More compli-
cated biocomposites have been developed as well. For
example, (A-W)/HDPE composite (AWPEX) biomaterials
have been designed to match the mechanical strength of
human cortical bone and to provide favorable bioactivity,
with potential use in many orthopedic applications [864–
867]. Other examples comprise wollastonite-reinforced
HA/Ca polycarboxylate [868] and glass-reinforced HAP/
polyacrylate [869] biocomposites.
HA/glass biocomposites can be prepared by simple
sintering of appropriate HA/glass powder mixtures [870–
873]. If sintering is carried out below 1000 C, HA does
not react with the bioactive glass [871, 872] or this reaction
is limited [873]. Besides, reaction between HA and glasses
depends on the glass composition. In another approach,
small quantities of bioactive glass have been added to HA
bioceramics in order to improve densification and/or
mechanical properties [26]. In addition, biocomposites
might be sintered from HA and silica [822]. In general,
bioactive glass–ceramics maintain a high strength for a
longer time than HA bioceramics under both the in vitro
and in vivo conditions [829, 834].
Carbon nanotubes with their small dimensions, a high-
aspect-ratio (length-to-diameter) as well as the exceptional
mechanical properties, including extreme flexibility and
strength, significant resistance to bending, high resilience
and the ability to reverse any buckling of the tube, have the
excellent potential to accomplish necessary mechanical
properties [874]. Recent studies have even suggested that
they may possess some bioactivity [875–878]. However,
due to a huge difference in shapes, it is a challenge to
prepare homogeneous mixtures of calcium orthophosphates
and carbon nanotubes: ‘‘one can imagine something similar
to achieving a homogeneous mixture of peas and spa-
ghetti’’ [874, p. 7]. Additionally, non-functionalized carbon
nanotubes tend to agglomerate and form bundles; besides,
they are soluble in neither water nor organic solvents.
Chemical functionalization allows carbon nanotubes to be
dispersed more easily, which can improve interfacial
bonding with calcium orthophosphates [247, 874].
Different strategies might be employed to prepare cal-
cium orthophosphate/carbon nanotubes biocomposites. For
example, apatites might be chemically synthesized using
carboxyl-functionalized carbon nanotubes as a matrix
[242–247]. Physico-chemical characterization of these
biocomposites showed that nucleation of CDHA initiates
through the carboxyl group [247]. Hot-pressing [879],
plasma spraying [880], and laser surface alloying [881–883]
techniques might be applied as well. The research on
calcium orthophosphate (up to now, only apatites)/carbon
nanotube biocomposites is in its early stages, with the first
papers published in 2004 [246, 433]. Due to this reason, the
mechanical property data for such biocomposites have
been reported only in few papers; however, these results
are encouraging. For example, Chen et al. [883] performed
nanoindentation tests on biocomposite coatings to give
hardness and Young’s modulus values. They found that the
higher the loading of nanotubes, the better the properties.
Namely, at 20 wt% loading, hardness was increased by
43% and Young’s modulus by 21% over a single-phase HA
coating [883]. Scratching test results indicated that as
alloyed HA biocomposite coatings exhibited improved
wear resistance and lower friction coefficient with
increasing the amount of carbon nanotubes in the precursor
material powders [882]. Additionally, measurements of the
elastic modulus and hardness of the biocomposite coatings
indicated that the mechanical properties were also affected
by the amount of carbon nanotubes [881]. Another research
group performed compression tests on bulk HA/nanotubes
biocomposites and found an increase in strength over sin-
gle-phase HA [246]. However, the highest compressive
strength they achieved for any material was only 102 MPa,
which is similar to that of cortical bone but much lower
than the typical values for dense HA [874]. More complex
formulations, such as poly-L-lysine/HA/carbon nanotube
hybrid nanocomposites, have also been developed [884].
Unfortunately, carbon nanotubes are very stable sub-
stances; they are neither bioresorbable nor biodegradable.
Therefore, during the in vivo bioresorption, the nanotubes
will get into the human body from the biocomposite matrix
and might cause uncertain health problems. Except of
carbon nanotubes, carbon fibers of microscopic dimensions
are also used to reinforce HA bioceramics [885–887].
The main disadvantage of HA reinforced by PSZ is
degradation of zirconia in wet environments [755, 760,
761, 783]. Transformation of the tetragonal ZrO2 to the
monoclinic phase on the surface results in formation of
microcracks and consequently lowers the strength of the
implant [888, 889].
An HA-based biocomposite reinforced with 20 vol.% of
Ti particles was fabricated by hot-pressing [840]. Besides,
calcium orthophosphates/Ti biocomposites might be pre-
pared by powder metallurgy processing [842–844]. At high
temperatures, the presence of Ti metal phase was found to
promote dehydration and decomposition of HA into b-TCP
and TTCP [840, 842] or partial formation of b-TCP and
calcium titanate instead of HA [554, 843, 844]. Comparing
with pure HA bioceramics manufactured under the same
conditions, the HA/Ti biocomposites possessed a higher
fracture toughness, bending strength, work of fracture,
porosity, and lower elastic modulus, which is more suitable
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for biomedical applications. However, the mechanical
properties appeared to be not high enough to use HA/Ti
biocomposites in load-bearing applications. Luckily, the
histological evaluations revealed that HA/Ti biocomposites
could be partially integrated with newborn bone tissues
after 3 weeks and fully osteointegrated at 12 weeks in vivo
[840]. Similar findings had been earlier made for HA
bioceramics reinforced by addition of silver particulates
(5–30 vol.%) and subsequent sintering of the HA/Ag
powder compacts [838, 839]. Other studies on calcium
orthophosphate/Ti biocomposites are available elsewhere
[845–848].
To conclude this part, biocomposites consisting of cal-
cium orthophosphates only should be briefly described.
First of all, BCP itself, consisting of HA and a- or b-TCP,
should be mentioned [23]. In the 1980s, BCP was called as
‘‘TCP ceramics complexed with HA’’ [890]. More to the
point, 70% HA-powder ? 30% HA-whisker biocomposites
have been fabricated by pressureless sintering, hot-press-
ing, and hot-isostatic pressing. These biocomposites were
found to exhibit an improved toughness, attaining the lower
fracture-toughness limit of bone without a decrease of
bioactivity and biocompatibility [891, 892]. Besides, a dual
HA biocomposite that combined two HA materials with
different porosities: HA with 75% porosity, for bone
ingrowth and HA with 0% porosity, for load-bearing was
manufactured. This dual HA biocomposite appeared to be
suitable for use as an implant material for spinal interbody
fusion as a substitute for iliac bone grafts, which could
eliminate the disadvantages associated with autograft har-
vesting [893]. A biodegradable nanocomposite porous
scaffold comprising a b-TCP matrix and HA nanofibres
was developed and studied for load-bearing bone tissue
engineering. HA nanofibres were prepared by a biomimetic
precipitation method, the inclusion of which significantly
enhanced the mechanical property of the scaffold, attaining
a compressive strength of 9.87 MPa, comparable to the
high-end value (2–10 MPa) of cancellous bone [894].
Functionally graded biocomposites
Although, in most cases, the homogeneous distribution of
filler(s) inside a matrix is required [355], there are com-
posites, where this is not the case. For example,
functionally graded materials (commonly referred to as
FGM) might be characterized by the intentional variations
in composition and/or structure gradually over volume,
resulting in corresponding changes in the properties of the
composite. The main feature of such materials is the
almost continuously graded composition that results in
two different properties at the two ends of the structure.
Such composites can be designed for specific function
and applications. Various approaches based on the bulk
(particulate processing), preform processing, layer pro-
cessing, and melt processing are used to fabricate the
functionally graded materials.
Bone is a biologically formed composite with variable
density ranging from very dense and stiff (the cortical
bone) to a soft and foamed structure (the trabecular bone).
Normally the outer part of long bones consists of cortical
bone with the density decreasing toward the core, where
the trabecular bone is found. The trabecular bone is porous
and the porosity is filled with osseous medulla [21, 22].
This brief description clearly indicates that bones are nat-
ural functionally graded composites.
The concept of FGM has been increasingly used for
biomaterial design and currently it remains to be an
important area of the research. For example, powder met-
allurgy methods have been used to fabricate HA/Ti
functionally graded biocomposite dental implants offering
the biocompatible HA on the tissue side and titanium on
the outer side for mechanical strength [895–897]. The
graded structure in the longitudinal direction contains more
Ti in the upper section and more HA in the lower section.
Actually, in the upper section the occlusal force is directly
applied and Ti offers the required mechanical performance;
in the lower part, which is implanted inside the bone, the
HA confers the bioactive and osteoconductive properties to
the material [895]. Since the optimum conditions of sin-
tering for Ti and HA are very different, HA/Ti functionally
graded biocomposites are difficult to fabricate and the
sintering conditions for their mixtures are obliged to
compromise. The expected properties of this implant are
shown in Fig. 3 [896]. Functionally graded HA/Ti bio-
composite coatings might be prepared by rf-plasma
spraying [898]. A functionally graded HA/PMMA bio-
composite was developed based on sedimentary HA
distributions in a PMMA viscous fluid, using a centrifuge
to avoid stress convergence on the interface. The stress–
strain curves of this biocomposite showed sufficient
strength for medical application along with the relaxation
of brittleness and fragility [448]. A three-layered graded
biocomposite membrane, with one face of 8% nano-car-
bonated CDHA/collagen/PLGA porous membrane, the
opposite face of pure PLGA non-porous membrane, the
middle layer of 4% nano-carbonated CDHA/collagen/
PLGA as the transition, was prepared through the layer-by-
layer casting method [512]. HA/glass FGM layers were
coated on titanium alloy (Ti–6Al–4V) substrates. The
design of these layers and the use of the glass were for
achieving a strong bonding between the FGM-layered
coatings and the substrates [899, 900]. More to the point, Ti
alloy substrate has been combined with HA granules spread
over the surface [901].
Functionally graded b-TCP/FA biocomposites combine
the biostability of FA with bioresorbable properties of
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b-TCP [902]. An interesting multilayered (each layer of
1-mm-thick) structure consisting of b-TCP/FA biocom-
posites with different molar ratios has been prepared,
giving rise to formation of an FGM (Fig. 4). After
implantation, the preferential dissolution of b-TCP phase
would result in functionally gradient porosity for bone
ingrowth [903]. HA/zirconia-graded biocomposites were
fabricated to enhance the mechanical properties of HA
while retaining its bone bonding property [791]. TiO2 and
HA were found to be a good combination for FGM pro-
viding both a gradient of bioactivity and a good mechanical
strength [903]. Besides, graded HA/CaCO3 biocomposite
structures for bone ingrowth have been developed as well
[904]. Functionally graded composite skull implants con-
sisting of polylactides, carbonateapatite, and CaCO3 are
known as well [318, 319]. The research in this field is quite
promising but currently the mechanical properties of the
available biocomposites are clearly in excess of the prop-
erties of bone [147].
Biosensors
A biosensor is a device for detection of an analyte that
combines a biological component with a physicochemical
detector component. Very briefly, it consists of three parts:
a sensitive biological element; a transducer or a detector
element that transforms the signal resulting from the
interaction of the analyte with the biological element into
another signal; and associated electronics that is primarily
responsible for the display of the results in a user-friendly
way [905].
The surface of biologically relevant calcium orthophos-
phates (CDHA, HA, a-TCP, b-TCP) has an excellent ability
of adsorption for functional biomolecules such as proteins,
albumins, DNA, and so on. Therefore, some calcium
orthophosphate-based biocomposites and hybrid biomate-
rials were found to be applicable for biosensor
manufacturing [288, 542, 851, 884]. For example, forma-
tion of poly-L-lysine/HA/carbon nanotube hybrid nano-
particles was described, and a general design strategy for an
immunosensing platform was proposed based on adsorption
of antibodies onto this nanocomposite [884]. In another
article, a hybrid material formed by assembling of gold
nanoparticles onto nano-HA was employed for the interface
design of piezoelectric immunosensor, on which the anti-
bodies were bound. The developed sensing interface
appeared to possess some advantages, such as activation-
free immobilization and high antigen-binding activities of
antibodies, over using either nano-HA or gold nanoparticles
alone [851]. Until now, just a few papers have been pub-
lished on biosensor application of calcium orthophosphate-
based biocomposites. Presumably, this subject will be
Fig. 3 Expected properties of functionally graded biocomposite
dental implant. For comparison, the upper drawing shows a
functionally graded implant and the lower one shows a conventional
uniform implant. The properties are shown in the middle. The implant
with the composition changed from a biocompatible metal (Ti) at one
end (left in the figure), increasing the concentration of bioceramics
(HA) toward 100% HA at the other end (right in the figure), could
control both mechanical properties and biocompatibility without an
abrupt change due to the formation of discrete boundary. This FGM
biocomposite was designed to provide more titanium for the upper
part where occlusal force is directly applied and more HA for the
lower part, which is implanted inside the jawbone. Reprinted from
Ref. [896] with permission
Fig. 4 A schematic diagram showing the arrangement of the FA/b-
TCP composite layers: a non-symmetric FGM, b symmetric FGM.
Reprinted from Ref. [902] with permission
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further developed in the future and, perhaps, sometime
implantable biosensors will be designed to perform the
continuous concentration monitoring of the important bio-
logical macromolecules. Possibly, those biocencors might
be able to use an electric power, generated by DCPD/
polymer composite-based battery devices [413, 414].
Interaction between the phases in calcium
orthophosphate-based biocomposites
An important aspect that should be addressed in details is a
mutual interaction between calcium orthophosphates and
other phases in biocomposites and hybrid biomaterials. In
general, an interaction between the phases in any com-
posite can be either mechanical, when it results from radial
compression forces exerted by the matrix on the filler
particles (e.g., developed during cooling due to thermal
contraction), or chemical, when the reactivity of the filler
toward the matrix has an important role. In the latter case,
it is important to distinguish a physical interaction from
chemical bonding [225]. According to Wypych [906],
physical interaction is more or less temporary, implicating
hydrogen bonding or van der Waals forces, whereas
chemical bonding is stronger and more permanent,
involving covalent bond formation. Thus, a chemical
interfacial bond between the phases is preferred to achieve
a higher strength of a composite. The magnitude of the
interfacial bond between the phases determines how well a
weak matrix transmits stress to the strong fibers. However,
while a bond between the matrix and reinforcement must
exist for the purpose of stress transfer, it should not be so
strong that it prevents toughening mechanisms, such as
debonding and fiber pullout [874].
There is still doubt as to the exact bonding mechanism
between bone minerals (biological apatite) and collagen,
which undoubtedly plays a critical role in determining the
mechanical properties of bones. Namely, bone minerals are
not directly bonded to collagen, but through non-collage-
nous proteins that make up *3% of bones (Table 1) and
provide with active sites for biomineralization and for
cellular attachment [32]. In bones, the interfacial bonding
forces are mainly ionic bonds, hydrogen bonds, and
hydrophobic interactions, which give the bones the unique
composite behavior [49]. There is an opinion that, opposite
to bones, there is no sign of chemical bonding between
phases in conventional calcium orthophosphate/collagen
biocomposites, probably due to a lack of suitable interfa-
cial bonding during mixing [35]. However, this is not the
case for phosphorylated collagens [633]. Anyway, Fourier-
transformed infrared (FTIR) spectra of some calcium
orthophosphate-based composites and collagen films were
measured and transformed into absorption spectra using the
Kramers-Kronig equation to demonstrate energy shifts of
residues on the HA/collagen interface. After comparing
FTIR spectra of biocomposites and collagen films in detail,
red shifts of the absorption bands for C–O bonds were
observed in the spectra of the biocomposites. These red
shifts were described as a decrease in bonding energies of
C–O bonds and assumed to be caused by an interaction to
Ca2? ions located on the surfaces of apatite nanocrystals,
as shown in Fig. 5 [628]. Another proof of a chemical
interaction between CDHA and collagen fibers was also
evaluated in FTIR spectra of CDHA/collagen biocompos-
ites, in which a shift of the band corresponding to –COO-
stretching from 1340 to 1337 cm-1 was observed [594,
595]. More to the point, nucleation of CDHA crystals onto
collagen through a chemical interaction with carboxylate
Fig. 5 A schematic diagram of
the relation between self-
organization (directional
deposition of HA on collagen)
and interfacial interaction in
biocomposites. Direction of
interaction between HA and
collagen is restricted by
covalent bond between COO
and Ca(2) to maintain regular
coordination number of 7.
Reprinted from Ref. [628] with
permission
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groups of collagen macromolecules has been reported
[907–909].
FTIR spectroscopy seems to be the major investigation
tool of a possible chemical bonding among the phases in
calcium orthophosphate-based biocomposites and hybrid
biomaterials [220, 280, 287, 289, 382, 420, 502, 517, 526,
529, 536, 539, 541, 544, 549, 556, 565, 570, 595, 633, 666,
667, 726, 910, 911]. For example, the characteristic bands
at 2918, 2850, and 1472 cm-1 for the hydrocarbon back-
bone of PE appeared to have zero shift in an HA/PE
biocomposite. However, in the case of polyamide, some of
the FTIR-bands indicated that the polar groups shifted
apparently: the bands at 3304, 1273, and 692 cm-1 derived
from stretching of N–H, stretching of C–N–H, and
vibrating of N–H moved to 3306, 1275, and 690 cm-1 in
an HA/polyamide biocomposite, respectively. Both
stretching (3568 cm-1) and vibrating (692 cm-1) modes of
hydroxyl in HA moved to 3570 and 690 cm-1 in the HA/
polyamide buicomposite, respectively, indicating the for-
mation of hydrogen bonds. Besides, the bands at 1094 and
1031 cm-1 of PO4 modes also shifted to 1093 and
1033 cm-1 in the HA/polyamide biocomposite. The bands
shift in a fingerprint area indicated that the hydroxyl and
orthophosphate on the surface of HA might interact with
plentiful carboxyl and amino groups of polyamide through
nucleophilic addition [220]. Comparable conclusions were
made for nano-HA/PVA [541], CDHA/alginate [595],
ACP/PPF [420], HA/maleic anhydride [289], and b-TCP/
PLLA [382] biocomposites, where a weak chemical bond
was considered to form between Ca2? ions located on the
nano-HA, CDHA, ACP, HA, or b-TCP surface, respec-
tively, and slightly polarized O atoms of C=O bonds in the
surrounding bioorganic compounds. Schematically, this
chemical interaction is shown in Fig. 6 [595].
Except of FTIR spectroscopy, other measurement tech-
niques are also able to show some evidences of a chemical
interaction between calcium orthophosphates and other
compounds in biocomposites [280, 382, 536, 539, 541, 911–
913]. For example, for CDHA/alendronate nanocrystals
such evidences were observed by thermogravimetric anal-
ysis: DTG plots of the nanocrystals appeared to be quite
different from those obtained from mechanical mixtures of
CDHA and calcium alendronate with similar compositions
[912]. Analogous DTG results were obtained for nano-HA/
PVA [541]. In the case of nano-HA/polyamide biocom-
posites, a hydrogen bonding between the phases was
detected by differential scanning calorimetry technique
[536]. Another example comprises application of the
dynamic mechanical analysis to investigate softening
mechanism of b-TCP/PLLA biocomposites [382]. In the
case of nano-HA/PVAP composites, the indirect evidences
of chemical bonding between the phases were found by
X-ray diffraction and thermogravimetric analysis [280]. A
strong structural correlation between the orientation of FA
crystallites and the gelatin within the FA/gelatin composite
spheres was discovered that indicated to a substantial reor-
ganization of the macromolecular matrix within the area of a
growing aggregate [366].
By means of the X-ray photo-electronic spectroscopy
(XPS) technique, binding energies of Ca, P, and O atoms
were found to have some differences between nano-HA
(Ca, 350.5 and 345.5; O, 530.2; P, 132.5 eV) and nano-HA/
konjac glucomannan/chitosan biocomposite (Ca, 352.1 and
347.4; O, 531.2; P, 133.4 eV), respectively [549]. Further
measurements by FTIR and X-ray diffraction revealed that
nano-HA was mainly linked with konjac glucomannan and
chitosan by hydrogen bonding among OH- and PO4
3- of
nano-HA and –C=O and –NH of konjac glucomannan and
chitosan copolymer and there was a stable interface formed
between the three phases in the biocomposite. Meanwhile,
coordinate bonding might be formed between Ca2? and
–NH. Stable interfaces have been formed among the three
phases in a biocomposite [549]. In HA/collagen biocom-
posites, a covalent bond formation between Ca2? of HA
and RCOO- of collagen molecules was found by XPS
[503]. Similar XPS observations were also made for sev-
eral other calcium orthophosphate-based biocomposites
[529, 556, 565].
The interaction and adhesion between calcium ortho-
phosphate fillers and respective matrixes have a significant
effect on the properties of particulate-filled reinforced
materials, being essential to transfer the load between the
phases and thus improve the mechanical performance of
the composites [287]. However, for the substantial amount
of the biocomposites discussed in this review, the inter-
action between the phases is mechanical in nature. This is
because the matrix often consists of compounds with no
functional groups or unsaturated bonds, which can form
ionic complexes with the constituents of calcium ortho-
phosphates. Obviously, less coupling exists between non-
polar polymers and calcium orthophosphate ceramic par-
ticles. Therefore, polymers with functional groups pendant
Fig. 6 A schematic diagram of Ca2? ion binding with alginate
chains. Reprinted from Ref. [595] with permission
J Mater Sci (2009) 44:2343–2387 2369
123
to the polymer backbone, which can act as sites for
bridging to calcium orthophosphates, are more promising
in this respect [49]. Besides, the surface of calcium or-
thophosphates might be modified as well [116, 416, 417,
552, 914, 915]. In order to improve the situation, various
supplementary reagents are applied. Namely, if the primary
effect of a processing additive is to increase the interaction
between the phases, such an additive can be regarded as a
coupling agent [916]. Coupling agents establish chemical
bridges between the matrix and the fillers, promoting the
adhesion between the phases. In many cases, their effect is
not unique, influencing also the rheology of composites
[225].
Optimization of biocomposite properties with coupling
agents is currently an important area of the research. The
control and development of molecular-level associations of
polymer with calcium orthophosphates is suggested to be
significant for the resulting mechanical responses in the
composites. It appears that a fundamental molecular
understanding of interfacial behavior in biocomposite
systems is an area not sufficiently addressed in the litera-
ture. Various experimental characterization techniques
using electron microscopy, vibrational spectroscopy, X-ray
diffraction, scanning probe microscopy, and others are used
routinely to characterize these materials besides mechani-
cal property characterization. In addition, atomic scale
models for simulating the phase interaction and predicting
responses in the novel material systems, where nanostruc-
ture and nanointerfaces are included, are important to
understand and predict the load deformation behavior
[147].
A hexamethylene diisocyanate coupling agent was used
to bind PEG/PBT (PolyactiveTM) block copolymers [234]
and other polymers [910] to HA filler particles. Thermo-
gravimetric and infrared analysis demonstrated that the
polymers were chemically bonded to the HA particles
through the isocyanate groups, making it a suitable
approach to improve the adhesion [910]. Other researchers
used glutaraldehyde as a crosslinked reagent in various
calcium orthophosphate-based biocomposites [388, 392,
500, 502, 503, 520, 525, 585, 621, 646, 649, 917]. The
interfacial bonding between calcium orthophosphates and
other components might be induced by using various
coupling agents and surface modifiers, such as silanes [192,
234, 337, 540, 918–923], zirconates [225, 337, 339, 914,
924], titanates [225, 337, 924], phosphoric acid [543],
alkaline pretreatment [722, 725], polyacids [115, 116, 234],
and other chemicals. Besides, some polymers might be
grafted onto the surface of calcium orthophosphates [552].
Structural modifications of the polymeric matrices, for
instance, with the introduction of acrylic acid [195, 234,
919, 920], have also proved to be effective methods. For
example, application of polyacids as a bonding agent for
HA/PolyactiveTM composites caused the surface-modified
HA particles to maintain better contact with the polymer at
fracture and improved mechanical properties [115, 116,
234]. The use of titanate and zirconate coupling agents
appeared to be very dependent on the molding technique
employed [225]. Silane-coupled HA powders were tested
before applying them as fillers in biodegradable composites
[921–923]. This treatment allowed HA withstanding the
attack of water without impairing overall bioactivity.
Besides, chemically modified reinforcement phase–matrix
interface was found to improve the mechanical properties
of the biocomposites. Examples of such interface-modified
biocomposites include chemically coupled HA/PE [919,
920], chemically formed HA/Ca poly(vinylphosphonate)
[283], and PLA/HA fibers [184]. These biocomposites are
able to consume a large amount of energy in the fracture.
The action of some coupling agents was found to
combine two distinct mechanisms: (i) crosslinking of the
polymeric matrix (valid for zirconate and titanate coupling
agents) and (ii) improvement of the interfacial interactions
between the major phases of the composites. This interfa-
cial adhesion improvement appeared to be much dependent
on the chemical nature (pH and type of metallic center) of
the coupling agents [337]. Several studies claimed that
silanes do interact with HA [192, 919–923]. It was shown
that a silicon-containing inter-phase existed between HA
and PE, which promoted the chemical adhesion between
the HA particles and the polymer. A silane-coupling agent
also facilitated penetration of PE into cavities of individual
HA particles, which resulted in enhanced mechanical
interlocking at the matrix-reinforcement interface [919,
920].
Addition of adhesion promoting agents might be an
alternative to improve the interaction between the fillers and
the matrix. For example, Morita et al. [925] used incorpo-
ration of 4-methacryloyloxyethyl trimellitate anhydride to
promote adhesion of the polymer to HA. In another study,
phosphoric ester was added to the liquid component of the
formulation [926]. Both the strength and the affinity index of
biocomposites were found to increase, probably due to the
effects of copolymerization.
Possible interactions between BCP and HPMC have
been investigated in IBS composites [736, 737, 927]. After
mixing, there was a decrease in the mean diameter of BCP
granules and this influenced the viscosity of the paste.
Dissolution of grain boundaries of b-TCP crystals and
precipitation of CDHA on HA crystal surface was found
during the interaction between BCP and HPMC in aqueous
solutions. Both phenomena were responsible for the
observed granulometric changes [736, 737]; however,
within the sensitivity of the employed measurement tech-
niques, no chemical bonding between BCP and HPMC was
detected [927].
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A coprecipitation method was used to prepare CDHA/
chitosan biocomposites [672]. Growth of CDHA crystals
was inhibited by organic acids with more than two car-
boxyl groups, which strongly bind to CDHA surfaces via a
COO–Ca bond. Transmission electron microscopy images
revealed that CDHA-formed elliptic aggregates with
chemical interactions (probably coordination bond)
between Ca on its surface and amino groups of chitosan;
the CDHA nanocrystals were found to align along the
chitosan molecules, with the amino groups working as the
nucleation sites [672]. Formation of calcium crosslinked
polymer carboxylate salts was suggested during the setting
of calcium orthophosphate cement (TTCP ? DCPA)/
polyphosphazane biocomposites; the chemical involvement
of the polymer in the cement setting was concluded based
on the results of pH monitoring [460–462].
A chemical bond between the phases was presumed in
PCL/HA composites, prepared by the grafting technique
[350]; unfortunately, no strong experimental evidences
were provided. In another study, CDHA/poly(a-hydroxy-
ester) composites were prepared by a low-temperature
chemical route [324]. In that study, pre-composite struc-
tures were prepared by combining a-TCP with PLA, PLGA
and copolymers thereof. The final biocomposite structure
was achieved by in situ hydrolysis of a-TCP to CDHA
performed at 56 C either in solvent cast or pressed pre-
composites. That transformation occurred without any
chemical reaction between the polymer and calcium
orthophosphates, as it was determined by FTIR spectros-
copy [324].
In nearly every study on HA/carbon nanotubes bio-
composites, the nanotubes have been functionalized before
combining them with HA. Most researchers have done this
by oxidation [242–246], although non-covalent function-
alizing with sodium dodecylsulfate [246] and coating the
nanotubes by a polymer [928] before combining them with
HA have also been reported. Several studies by transmis-
sion electron microscopy have shown evidences that the
functionalization has enhanced interaction between carbon
nanotubes and HA [245, 246, 929].
If calcium orthophosphate-based biocomposites are able
to sustain a high-temperature sintering (valid for the for-
mulations consisting of inorganic components only), an
inter-diffusion of chemical elements will take place
between the phases. Such effect has been detected by
energy-dispersive X-ray spectroscopy in HA/TiO2 bio-
composite particles with partial formation of calcium
titanates; this process was found to be favorable to
enhancing the cohesive strength of particles in the
composite coating [817]. A similar high-temperature
interaction between HA and zirconia [743, 768], as well as
between HA and Ti [554, 840, 842–844], was also detec-
ted. Besides, partial decomposition of HA and formation of
different calcium aluminates were detected in HA/Al2O3
biocomposites after sintering at 1200–1300 C [795, 801,
802].
Bioactivity and biodegradation of calcium
orthophosphate-based biocomposites
The continuous degradation of an implant causes a gradual
load transfer to the healing tissue, preventing stress-
shielding atrophy and stimulates the healing and remodel-
ing of bones. Some requirements must be fulfilled by the
ideal prosthetic biodegradable materials, such as biocom-
patibility, adequate initial strength and stiffness, retention
of mechanical properties throughout sufficient time to
assure its biofunctionality and non-toxicity of the degra-
dation by-products [146]. Generally speaking, bioactivity
(i.e., ability of bonding to bones) of biologically relevant
calcium orthophosphates reinforced by other materials is
usually lower than that of pure calcium orthophosphates
[27, 28, 930].
In general, both bioactivity and biodegradability of any
biocomposite are determined by the same properties of the
constituents. Both processes are very multi-factorial
because, after implantation, the surface of any graft is
rapidly colonized by cells. Much more biology, than
chemistry and material science altogether, is involved into
these very complex processes and many specific details
still remain unknown. In order to simplify the task, the
biodegradability of the biologically relevant calcium
orthophosphates might be described by a chemical disso-
lution in slightly acidic media (calcium orthophosphates
are almost insoluble in alkaline solutions [87–93]), which,
in the case of CDHA, might be described as a sequence of
four successive chemical equations [427, 931, 932]:
Ca10x HPO4ð Þx PO4ð Þ6x OHð Þ2x þ 2  xð ÞHþ
! Ca10x HPO4ð Þx PO4ð Þ6x H2Oð Þ2x 2xð Þþ ð1Þ
Ca10x HPO4ð Þx PO4ð Þ6x H2Oð Þ2x 2xð Þþ
! 3Ca3 PO4ð Þ2 þ 1  xð ÞCa2þ þ 2  xð ÞH2O ð2Þ
Ca3 PO4ð Þ2 þ 2Hþ ! Ca2þ þ 2CaHPO4 ð3Þ
CaHPO4 þ Hþ ! Ca2þ þ H2PO4 ð4Þ
Strange enough, but the bioactivity mechanism of
calcium orthophosphates is not well described in
literature; therefore, biomaterials researchers [72] are
forced to use a modified scheme for the bioactivity
mechanism of bioactive glasses—the concept introduced
by Prof. Hench [27, 28]. The mechanism of bonding of
bioactive glasses to living tissue involves a sequence of 11
successive reaction steps. The initial five steps occurred on
the surface of bioactive glasses are ‘‘chemistry’’ only,
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whereas the remaining six steps belong to ‘‘biology’’
because the latter include colonization by osteoblasts,
followed by proliferation and differentiation of the cells to
form a new bone that had a mechanically strong bond to the
implant surface (Fig. 7).
Biodegradability of polymers generally depends on the
following factors: (1) chemical stability of the polymer
backbone, (2) hydrophobicity of the monomer, (3) mor-
phology of the polymer, (4) initial molecular weight, (5)
fabrication processes, (6) geometry of the implant, (7)
properties of the scaffold such as porosity and pore diam-
eter [264]. A summary on degradation of PLA and PGA, as
well as that of starch/ethylene vinyl alcohol copolymer
(SEVA) is available in literature [146, p. 798 and p. 803,
respectively], where the interested readers are referred to.
Biodegradation of HA/PLLA and CDHA/PLLA composite
rods in subcutis and medullary cavities of rabbits were
investigated mechanically and histologically; the degrada-
tion was found to be faster for the case of using
uncalcinated CDHA instead of calcinated HA [933]. In a
more detailed study, new bone formation was detected at
2 weeks after implantation, especially for formulations
with a high HA content [934]. More to the point, a direct
contact between bones and these composites without
intervening fibrous tissue was detected in this case [934,
935]. SEVA-C and SEVA-C/HA biocomposites were
found to exhibit a non-cytotoxic behavior [936, 937],
inducing a satisfactory tissue response when implanted as
shown by in vivo studies [937]. Furthermore, SEVA-C/HA
biocomposites induce a positive response on osteoblast-like
cells to what concerns cell adhesion and proliferation
[936].
Both in vitro (the samples were immersed into 1%
trypsin/phosphate-buffered saline solution at 37 C) and in
vivo (implantation of samples into the posterolateral lum-
bar spine of rabbits) biodegradation have been investigated
for nano-HA/collagen/PLA biocomposites [511]. The
results demonstrated that weight loss increased continu-
ously in vitro with a reduction in mass of 19.6% after
4 weeks. During the experimental period in vitro, the rel-
ative rate of reduction of the three components in this
material was shown to differ greatly: collagen decreased
the fastest, from 40% by weight to 20% in the composite;
HA content increased from 45 to 60%, whereas PLA
changed little. In vivo, the collagen/HA ratio appeared to
be slightly higher near the transverse process than in the
central part of the intertransverse process [511]. These data
clearly demonstrate a biodegradation independence of
various components of biocomposites.
Some challenges and critical issues
The scientific information summarized in this review
represents the recent developments of calcium ortho-
phosphate-based biocomposites and hybrid biomaterials
Fig. 7 The sequence of
interfacial reactions involved in
forming a bond between tissue
and bioactive glasses. The
border between ‘‘dead’’ and
‘‘alive’’ occurs approximately at
stage 6. For want of anything
better, the bioactivity
mechanism of calcium
orthophosphates should also be
described by this scheme with
omitting of several initial
stages, as it was made for HA in
Ref. [72], where three initial
chemical stages of the Hench’s
mechanism were replaced by
partial dissolution of HA.
Reprinted from Ref. [28] with
permission
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from a variety of approaches, starting from conventional
ones to tissue engineering. Such formulations combined
with osteoconductive, osteoinductive factors, and/or
osteogenic cells have gained much interest as a new and
versatile class of biomaterials, and are perceived to be
beneficial in many aspects as bone grafts [32]. However,
current applications of these biomaterials in medicine
and surgery are still remarkably less than might be
expected. In many biomedical applications, research and
testing of such formulations have been introduced and
highly developed but only in a very few cases an
industrial production and commercial distribution of
medical devices partially or entirely made of biocom-
posites have started. The medical application of
biocomposites and hybrid biomaterials requires a better
understanding of the objectives and limitations involved.
Recently, the main critical issues have been summarized
as follows [213]:
• There are not enough reliable experimental and clinical
data supporting the long-term performance of biocom-
posites with respect to monolithic traditional materials.
• The design of biocomposites and hybrid biomaterials is
far more complex than that of conventional monolithic
materials because of the large number of additional
design variables that must be considered.
• The available fabrication methods may limit the
possible reinforcement configurations, may be time
consuming, expensive, highly skilled and may require
special cleaning and sterilization processes.
• There are no satisfactory standards yet for biocompat-
ibility testing of the biocomposite implants because the
ways in which the different components of any
biocomposite interact to living tissues are not com-
pletely understood.
• There are no adequate standards for the assessment of
biocomposite fatigue performance because the fatigue
behavior of such materials is far more complex and
difficult to predict than that of traditional materials
[213].
On the other hand, in spite of an enormous progress in
biocomposite processing, to achieve the desired charac-
teristics researchers still need to develop more advanced
technologies to fabricate a bone-resembling hierarchical
organization over several length scales. Development of
novel bone repair materials depends on the progress in
research into the structure of natural bones. The key issues
are not only to understand the fundamentals of biominer-
alization, but also to translate such knowledge into
practical synthetic pathways to produce better bone grafts.
Unfortunately, when it comes to the fabrication of com-
posites mimicking natural bone from the nanometer to the
micrometer dimensions, there are many key issues,
including the control of morphology, incorporation of
foreign ions, interaction with biomolecules, and assembly
of the organic and inorganic phases, which are still not well
understood. A processing gap between the lower-level
building units and the higher-order architecture could
severely limit the practical application of current calcium
orthophosphate-based biocomposites and hybrid biomate-
rials. Therefore, further substantial research efforts have
been outlined to address the following key challenges [32,
37]:
• Optimizing biocomposite processing conditions.
• Optimization of interfacial bonding and strength equiv-
alent to natural bone.
• Optimization of the surface properties and pore size to
maximize bone growth.
• Maintaining the adequate volume of the construct in
vivo to allow bone formation to take place.
• Withstanding the load-bearing conditions.
• Matching the bioresorbability of the grafts and their
biomechanical properties while forming new bone.
• Understanding the molecular mechanisms by which the
cells and the biocomposite matrix interact with each
other in vivo to promote bone regeneration.
• Supporting angiogenesis and vascularization for the
growth of healthy bone cells and subsequent tissue
formation and remodeling [32, 37].
The aforementioned critical issues have to be solved
before a widespread commercial use of calcium ortho-
phosphate-based biocomposites and hybrid biomaterials
can be made in surgery and medicine.
Conclusions
All types of calcified tissues of humans and mammals
appear to possess a complex hierarchical composite struc-
ture. Their mechanical properties are outstanding
(considering weak constituents from which they are
assembled) and far beyond those, that can be achieved
using the same synthetic materials with present technolo-
gies. This is because biological organisms produce
biocomposites that are organized in terms of both compo-
sition and structure, containing both brittle calcium
orthophosphates and ductile bioorganic components in very
complex structures, hierarchically organized at the nano-,
micro-, and meso-levels. Additionally, the calcified tissues
are always multifunctional, e.g., bone provides structural
support for the body plus blood cell formation. The third
defining characteristic of biological systems, in contrast
with current synthetic systems, is their self-healing ability,
which is nearly universal in nature. These complex struc-
tures, which have risen from millions of years of evolution,
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inspire materials scientists in the design of novel bioma-
terials [938].
Until now, still no reasonable alternative exists to
autogenous bone grafts in surgery. However, the studies
summarized in this review have shown that the proper
combination of a ductile matrix with a brittle, hard, and
bioactive calcium orthophosphate filler offers many
advantages for biomedical applications. Namely, the
desirable properties of some components can compensate
for a poor mechanical behavior of calcium orthophosphate
bioceramics, while in turn the desirable bioactive proper-
ties of calcium orthophosphates improve those of other
phases, thus expanding the possible application of each
material within the body [94]. However, the reviewed lit-
erature clearly indicates that among possible types of
calcium orthophosphate-based biocomposites and hybrid
biomaterials only simple, complex, and graded ones (see
classification of the composites in the section ‘‘General
information on composites and biocomposites’’) have been
investigated. Presumably, a future progress in this subject
will require concentrating efforts on elaboration and
development of hierarchical biocomposites. Furthermore,
following the modern tendency of tissue engineering, a
novel generation of calcium orthophosphate-based bio-
composites and hybrid biomaterials should also contain a
biological living part.
Much study remains to be done on a long way from a
laboratory to clinics, and the success in this field depends
on the effective cooperation of clinicians, chemists, biol-
ogists, bioengineers, and materials scientists.
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